Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
37d8cacbb73c25560f4f8867604e24cf60191a34e89b2f6e07d06a6bb6e43f1f.png
complex
<table><tr><td colspan="2">Branch and Terminal Node Number and Description</td><td>N</td><td>AT%</td><td>Mean Distance</td></tr><tr><td>Node</td><td>Suburban branch</td><td></td><td></td><td></td></tr><tr><td>1.</td><td>Front porch &gt; 0.83, driveways &lt; 0.83, sidewalks &gt; 0.67</td><td>136</td><td>7 <sup>4,8,9,11,12</sup></td><td>1366.45 <sup>2,4&#8211;12</sup></td></tr><tr><td>2.</td><td>Blank walls &gt; 0.26, front porch &lt; 0.83, driveways &lt; 0.83, sidewalks &gt; 0.67</td><td>39</td><td>23 <sup>8,9,11,12</sup></td><td>688.55 <sup>1,4,5,11,12</sup></td></tr><tr><td>3.</td><td>Blank walls &lt; 0.26, front porch &lt; 0.83, driveways &lt; 0.83, sidewalks &gt; 0.67</td><td>8</td><td>75</td><td>1245.7412</td></tr><tr><td></td><td>Urban branch</td><td></td><td></td><td></td></tr><tr><td>4.</td><td>Zebra crosswalks &lt; 0.03, driveways &gt; 0.83, sidewalks &gt; 0.67</td><td>137</td><td>23 <sup>1,8,9,11,12</sup></td><td>1123.83 <sup>1,2,6&#8211;12</sup></td></tr><tr><td>5.</td><td>Traffic/pedestrian signals &gt; 0.44, zebra crosswalks &gt; 0.03, driveways &gt; 0.83, sidewalks &gt; 0.67</td><td>60</td><td>25 <sup>8,9,11,12</sup></td><td>1105.56 <sup>1,2,6&#8211;12</sup></td></tr><tr><td>6.</td><td>Curb cut &lt; 0.91, decorative sidewalks &gt; 0.21, zebra crosswalks &gt; 0.03, driveways &gt; 0.83, sidewalks &gt; 0.67</td><td>31</td><td>29 <sup>9,11,12</sup></td><td>464.75 <sup>1,4,5,7,8,10,12</sup></td></tr><tr><td>7.</td><td>Sidewalk buffer &gt; 0.93, curb cut &gt; 0.91, decorative sidewalks &gt; 0.21, traffic/pedestrian signals &lt; 0.44, zebra crosswalks &gt; 0.03, driveways &gt; 0.83, sidewalks &gt; 0.67</td><td>24</td><td>42 <sup>1,2</sup></td><td>739.21 <sup>1,4&#8211;6,9,11,12</sup></td></tr><tr><td>8.</td><td>Sidewalk buffer &lt; 0.93, curb cut &gt; 0.91, decorative sidewalks &gt; 0.21, traffic/pedestrian signals &lt; 0.44, zebra crosswalks &gt; 0.03, driveways &gt; 0.83, sidewalks &gt; 0.67</td><td>14</td><td>79 <sup>1,2,4,5</sup></td><td>739.6 <sup>1,4&#8211;6,9,11,12</sup></td></tr><tr><td>9.</td><td>Decorative sidewalks &lt; 0.21, traffic/pedestrian signals &lt; 0.44, zebra crosswalks &gt; 0.03, driveways &gt; 0.83, sidewalks &gt; 0.67</td><td>26</td><td>77 <sup>1,2,4&#8211;6</sup></td><td>401.25 <sup>1,4,5,7,8,10,12</sup></td></tr><tr><td></td><td>Alley branch</td><td></td><td></td><td></td></tr><tr><td>10.</td><td>Crosswalks &lt; 0.14, convenient to cross segment &lt; 0.15, sidewalks &gt; 0.67</td><td>18</td><td>39 <sup>1,2</sup></td><td>774.1 <sup>1,4&#8211;6,9,11,12</sup></td></tr><tr><td>11.</td><td>Crosswalks &gt; 0.14, convenient to cross segment &lt; 0.15, sidewalks &gt; 0.67</td><td>18</td><td>78 <sup>1,2,4&#8211;6</sup></td><td>297.85 <sup>1,2,4,5,7,8,10</sup></td></tr><tr><td>12.</td><td>Convenient to cross segment &gt; 0.15, sidewalks &lt; 0.67</td><td>25</td><td>100 <sup>4,8,9,11,12</sup></td><td>137.18 <sup>1&#8211;10</sup></td></tr></table>
02f9d9fc5378fbfb06b05242c19d41e2d203a6a630df24bc40e262cd06f854e7.png
complex
<table><tr><td></td><td></td><td colspan="3">Number (%) of patients</td><td></td></tr><tr><td></td><td></td><td>with PE (N = 107)</td><td>without PE (N = 7175)</td><td>total (N = 7282)</td><td><i>P*</i></td></tr><tr><td>Metabolic syndrome</td><td>yes</td><td>26 (2.7)</td><td>932 (97.3)</td><td>958</td><td>0.001</td></tr><tr><td></td><td>no</td><td>81 (1.3)</td><td>6243 (98.7)</td><td>6324</td><td></td></tr><tr><td rowspan="2">Number of metabolic syndrome components</td><td>0</td><td>16 (0.85)</td><td>1872 (99.15)</td><td>1888</td><td>&lt;0.003</td></tr><tr><td>1</td><td>31 (1.24)</td><td>2469 (98.76)</td><td>2500</td><td></td></tr><tr><td></td><td>2</td><td>34 (1.76)</td><td>1902 (98.24)</td><td>1936</td><td></td></tr><tr><td></td><td>3</td><td>21 (2.64)</td><td>775 (97.36)</td><td>796</td><td></td></tr><tr><td></td><td>4</td><td>5 (3.09)</td><td>157 (96.91)</td><td>162</td><td></td></tr><tr><td colspan="3">Individual components of metabolic syndrome</td><td></td><td></td><td></td></tr><tr><td>body mass index</td><td>&lt;30 kg/m<sup>2</sup></td><td>38 (0.9)</td><td>3966 (99.1)</td><td>4004</td><td>&lt;0.001</td></tr><tr><td></td><td>&#8805;30 kg/m<sup>2</sup></td><td>69 (2.1)</td><td>3209 (97.9)</td><td>3278</td><td></td></tr><tr><td>dyslipidemia</td><td></td><td>26 (2.7)</td><td>932 (97.3)</td><td>958</td><td>0.169</td></tr><tr><td>hypertension</td><td></td><td>68 (1.8)</td><td>3806 (98.2)</td><td>3874</td><td>0.032</td></tr><tr><td>dysglycemia</td><td></td><td>19 (2.1)</td><td>867 (97.9)</td><td>886</td><td>0.099</td></tr></table>
5d27277dbf27df6dcc0c93bb2183aee3a8f1fbc6ba0baafbe54436abbe8afd47.png
simple
<table><tr><td># Gene ID Gene Description</td></tr><tr><td>AKAP11 A-kinase anchor protein 11 2</td></tr><tr><td>AKR1A1 alcohol dehydrogenase 3</td></tr><tr><td>ATP5O ATP synthase subunit O, mitochondrial precursor 4</td></tr><tr><td>C1orf109 hypothetical protein LOC54955 5</td></tr><tr><td>C2orf29 hypothetical protein LOC55571 6</td></tr><tr><td>C9orf123 transmembrane protein C9orf123 7</td></tr><tr><td>CDK9 cell division protein kinase 9 8</td></tr><tr><td>CHSY1 chondroitin sulfate synthase 1 9</td></tr><tr><td>CKAP2L cytoskeleton-associated protein 2-like 10</td></tr><tr><td>CLINT1 clathrin interactor 1 11</td></tr><tr><td>DUSP2 dual specificity protein phosphatase 2 12</td></tr><tr><td>DUSP6 dual specificity protein phosphatase 6 isoform 13</td></tr><tr><td>HSPC157 hypothetical LOC29092 14</td></tr><tr><td>KIAA0427 CBP80/20-dependent translation initiation factor 15</td></tr><tr><td>LDHA L-lactate dehydrogenase A chain isoform 5 16</td></tr><tr><td>LOC100188949 hypothetical LOC100188949 17</td></tr><tr><td>LOC285456 hypothetical LOC285456 18</td></tr><tr><td>LSM14B protein LSM14 homolog B 19</td></tr><tr><td>MAX protein max isoform a 20</td></tr><tr><td>MRPS18A 28S ribosomal protein S18a, mitochondrial 21</td></tr><tr><td>MTF2 metal-response element-binding transcription 22</td></tr><tr><td>NAIF1 nuclear apoptosis-inducing factor 1 23</td></tr><tr><td>NDUFA10 NADH dehydrogenase [ubiquinone] 1 alpha 24</td></tr><tr><td>POMP proteasome maturation protein 25</td></tr><tr><td>PSMA6 proteasome subunit alpha type-6 26</td></tr><tr><td>RBM16 putative RNA-binding protein 16 27</td></tr><tr><td>RBM38 RNA-binding protein 38 isoform a 28</td></tr><tr><td>RPN1 dolichyl-diphosphooligosaccharide--protein 29</td></tr><tr><td>SEPHS2 selenide, water dikinase 2 30</td></tr><tr><td>SIRPG signal-regulatory protein gamma isoform 1 31</td></tr><tr><td>SPRED2 sprouty-related, EVH1 domain-containing protein 32</td></tr><tr><td>TFRC transferrin receptor protein 1 33</td></tr><tr><td>TMEM18 transmembrane protein 18 34</td></tr><tr><td>TRIP13 thyroid receptor-interacting protein 13 isoform 35</td></tr><tr><td>TXN2 thioredoxin, mitochondrial precursor 36</td></tr><tr><td>UBE2D2 ubiquitin-conjugating enzyme E2 D2 isoform 1 37</td></tr><tr><td>ZFAT zinc finger protein ZFAT isoform 1 38</td></tr><tr><td>ZNF212 zinc finger protein 212 39</td></tr><tr><td>ZNF683 zinc finger protein 683</td></tr></table>
663f4502ef940b47563185fb6dd16307b43b895fdb4fe1bbe8e514e6ad2bf6f2.png
simple
<table><tr><td>Part</td><td>Number of sub-parts</td><td>Number of guidance points</td></tr><tr><td>Leadership</td><td>8</td><td>93</td></tr><tr><td>Policy and strategy</td><td>5</td><td>43</td></tr><tr><td>People management</td><td>6</td><td>60</td></tr><tr><td>Resources</td><td>7</td><td>54</td></tr><tr><td>Processes</td><td>4</td><td>29</td></tr><tr><td>Customer and society results</td><td>2</td><td>43</td></tr><tr><td>People results</td><td>2</td><td>36</td></tr><tr><td>Contractor results</td><td>2</td><td>33</td></tr><tr><td>Key performance results</td><td>2</td><td>19</td></tr><tr><td>Total</td><td>38</td><td>410</td></tr></table>
5a89a5c42def5a50cd06cdf505a4522ee073a81ba0a4e7c479dad51428f4c7e9.png
complex
<table><tr><td>Variable</td><td></td><td>N (92,082)</td><td>% (100.0)</td></tr><tr><td rowspan="5">Age (years)</td><td>30&#8211;39</td><td>20,069</td><td>21.8</td></tr><tr><td>40&#8211;49</td><td>23,377</td><td>25.4</td></tr><tr><td>50&#8211;59</td><td>19,776</td><td>21.5</td></tr><tr><td>60&#8211;69</td><td>15,954</td><td>17.3</td></tr><tr><td>&#8805;70</td><td>12,906</td><td>14.0</td></tr><tr><td rowspan="4">Smoking status</td><td>Non-smoking</td><td>21,147</td><td>23.0</td></tr><tr><td>Smoking</td><td>70,935</td><td>77.0</td></tr><tr><td>Current smoking</td><td>43,088</td><td>46.8</td></tr><tr><td>Ex smoking</td><td>27,847</td><td>30.2</td></tr><tr><td rowspan="7">Period of smoking (Years)</td><td>Non-smoking</td><td>21,147</td><td>23.0</td></tr><tr><td>0&#8211;9</td><td>7531</td><td>8.0</td></tr><tr><td>10&#8211;19</td><td>20,384</td><td>22.1</td></tr><tr><td>20&#8211;29</td><td>19,845</td><td>21.6</td></tr><tr><td>30&#8211;39</td><td>12,645</td><td>13.7</td></tr><tr><td>40&#8211;49</td><td>7150</td><td>7.8</td></tr><tr><td>&#8805;50</td><td>3509</td><td>3.8</td></tr><tr><td rowspan="2">Physician-diagnosed stroke</td><td>Yes</td><td>2380</td><td>2.6</td></tr><tr><td>No</td><td>89,699</td><td>97.4</td></tr><tr><td rowspan="2">Physician-diagnosed myocardial infarction</td><td>Yes</td><td>1387</td><td>1.5</td></tr><tr><td>No</td><td>90,695</td><td>98.5</td></tr><tr><td rowspan="2">Physician-diagnosed hypertension</td><td>Yes</td><td>19,040</td><td>20.7</td></tr><tr><td>No</td><td>72,985</td><td>79.3</td></tr><tr><td rowspan="2">Physician-diagnosed diabetes</td><td>Yes</td><td>7991</td><td>8.7</td></tr><tr><td>No</td><td>84,050</td><td>91.3</td></tr></table>
ce4236710e887a3795b3f142db5a8d812edb50983e2ebe08549d7b6f0f825734.png
simple
<table><tr><td></td><td>Nutridrink</td><td>Impact</td><td>Return to Nutridrink</td><td><i>p</i></td></tr><tr><td>Body weight (kg)</td><td>57 &#177; 5.8</td><td>57 &#177; 5.9</td><td>58 &#177; 5.8</td><td>NS</td></tr><tr><td>Systolic BP (mmHg)</td><td>115 &#177; 11</td><td>110 &#177; 7</td><td>117 &#177; 11</td><td>0.012</td></tr><tr><td>Diastolic BP (mmHg)</td><td>69 &#177; 9</td><td>64 &#177; 8</td><td>69 &#177; 9</td><td>0.03</td></tr><tr><td>Heart rate (pulse/min)</td><td>88 &#177; 15</td><td>77 &#177; 17</td><td>80 &#177; 14</td><td>0.002</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>18.8 &#177; 1.7</td><td>18.9 &#177; 1.6</td><td>19 &#177; 1.6</td><td>NS</td></tr></table>
2498a02953e3717965f69649dbd213a807521790906f533aedf17c6671b717a6.png
complex
<table><tr><td rowspan="2">Variable</td><td>Overall</td><td>Girls</td><td>Boys</td><td><i>p</i>-Value</td></tr><tr><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td>(Chi-Square Test)</td></tr><tr><td>Physical activity level</td><td></td><td></td><td></td><td></td></tr><tr><td> Sedentary</td><td>98 (36.8)</td><td>48 (41.0)</td><td>50 (33.6)</td><td rowspan="4">0.252</td></tr><tr><td> Moderate</td><td>60 (22.6)</td><td>28 (23.9)</td><td>32 (21.5)</td></tr><tr><td> Vigorous</td><td>108 (40.6)</td><td>41 (35.0)</td><td>67 (45.0)</td></tr><tr><td> MVPA (moderate and vigorous)</td><td>168 (63.2)</td><td>69 (59.0)</td><td>99 (66.4)</td></tr><tr><td>Activity type</td><td></td><td></td><td></td><td></td></tr><tr><td> Sports games</td><td>8 (3.0)</td><td>0 (0)</td><td>8 (5.4)</td><td rowspan="5">0.019 *</td></tr><tr><td> Active games</td><td>22 (8.3)</td><td>5 (4.3)</td><td>17 (11.4)</td></tr><tr><td> Sedentary activities</td><td>37 (13.9)</td><td>18 (15.4)</td><td>19 (12.8)</td></tr><tr><td> Locomotion</td><td>39 (14.7)</td><td>20 (17.1)</td><td>19 (12.8)</td></tr><tr><td> Activities on playground equipment</td><td>160 (60.2)</td><td>74 (63.3)</td><td>86 (57.7)</td></tr><tr><td>Group size</td><td></td><td></td><td></td><td></td></tr><tr><td> Alone (without other persons)</td><td>63 (23.8)</td><td>26 (22.4)</td><td>37 (24.8)</td><td rowspan="4">0.712</td></tr><tr><td> Small (2 to 4 persons)</td><td>186 (70.2)</td><td>84 (72.4)</td><td>102 (68.5)</td></tr><tr><td> Medium (5 to 9 persons)</td><td>14 (5.3)</td><td>5 (4.3)</td><td>9 (6.0)</td></tr><tr><td> Large (10 and more persons)</td><td>2 (0.8)</td><td>1 (0.9)</td><td>1 (0.7)</td></tr><tr><td>Usage of playground equipment</td><td></td><td></td><td></td><td>Fisher&#8217;s exact test</td></tr><tr><td> Things to hang from</td><td>14 (5.3)</td><td>6 (5.1)</td><td>8 (5.4)</td><td>1</td></tr><tr><td> Things to slide down</td><td>33 (12.5)</td><td>10 (8.6)</td><td>23 (15.5)</td><td>0.095</td></tr><tr><td> Things to climb up</td><td>30 (11.3)</td><td>15 (12.8)</td><td>15 (10.1)</td><td>0.560</td></tr><tr><td> Things to climb through</td><td>3 (1.1)</td><td>0 (0)</td><td>3 (2.0)</td><td>0.258</td></tr><tr><td> Things to stand/walk on</td><td>15 (5.7)</td><td>11 (9.4)</td><td>4 (2.7)</td><td>0.030 *</td></tr><tr><td> Swings</td><td>44 (16.6)</td><td>24 (20.5)</td><td>20 (13.5)</td><td>0.138</td></tr><tr><td> Carousels</td><td>8 (3.0)</td><td>5 (4.3)</td><td>3 (2.0)</td><td>0.308</td></tr><tr><td> See-saws</td><td>4 (1.5)</td><td>1 (0.9)</td><td>3 (2.0)</td><td>0.633</td></tr><tr><td> Playing fields</td><td>8 (3.0)</td><td>2 (1.7)</td><td>6 (4.0)</td><td>0.472</td></tr><tr><td> Sandpits</td><td>18 (6.8)</td><td>11 (9.4)</td><td>7 (4.7)</td><td>0.147</td></tr></table>
4116cbc1cbb97952c5fa484edb9cf0a53a03ca916a6f2c65899fe51dbc6d0d1c.png
simple
<table><tr><td>Characteristics</td><td>n<sup>&#163;</sup></td><td>Mean</td><td>SD</td><td>Median</td><td>p-value</td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td><td></td><td>0.7011*</td></tr><tr><td>White</td><td>1756</td><td>110.7</td><td>56</td><td>106.9</td><td></td></tr><tr><td>Non-white</td><td>433</td><td>109.3</td><td>56</td><td>107.3</td><td></td></tr><tr><td>Age (years)</td><td></td><td></td><td></td><td></td><td>0.5204*</td></tr><tr><td>&#8804; 29</td><td>1254</td><td>109.9</td><td>56.9</td><td>106.4</td><td></td></tr><tr><td>&gt; 29</td><td>935</td><td>111.1</td><td>54.8</td><td>107.4</td><td></td></tr><tr><td>Parity</td><td></td><td></td><td></td><td></td><td>0.0342*</td></tr><tr><td>Nullipara</td><td>1168</td><td>107.7</td><td>55.5</td><td>106.1</td><td></td></tr><tr><td>&#8805; 1</td><td>1021</td><td>113.4</td><td>56.4</td><td>107.5</td><td></td></tr><tr><td>Gestational age (US)</td><td></td><td></td><td></td><td></td><td>&lt; 0.0001**</td></tr><tr><td>13</td><td>18</td><td>18.3</td><td>6.9</td><td>18.7</td><td></td></tr><tr><td>14</td><td>43</td><td>23.3</td><td>7.5</td><td>23.4</td><td></td></tr><tr><td>15</td><td>59</td><td>27.2</td><td>8.1</td><td>26.5</td><td></td></tr><tr><td>16</td><td>60</td><td>39.5</td><td>13.5</td><td>35.8</td><td></td></tr><tr><td>17</td><td>61</td><td>44.1</td><td>17.0</td><td>41.7</td><td></td></tr><tr><td>18</td><td>60</td><td>45.3</td><td>18.1</td><td>41.4</td><td></td></tr><tr><td>19</td><td>62</td><td>69.3</td><td>21.3</td><td>66.2</td><td></td></tr><tr><td>20</td><td>110</td><td>67.9</td><td>22.1</td><td>64.4</td><td></td></tr><tr><td>21</td><td>102</td><td>81.6</td><td>32.1</td><td>76.6</td><td></td></tr><tr><td>22</td><td>91</td><td>86.7</td><td>33.2</td><td>80.7</td><td></td></tr><tr><td>23</td><td>82</td><td>95.5</td><td>35.1</td><td>87.1</td><td></td></tr><tr><td>24</td><td>60</td><td>115.2</td><td>35.0</td><td>115.6</td><td></td></tr><tr><td>25</td><td>59</td><td>113.5</td><td>37.6</td><td>114.3</td><td></td></tr><tr><td>26</td><td>62</td><td>120.2</td><td>37.2</td><td>120.9</td><td></td></tr><tr><td>27</td><td>62</td><td>125.6</td><td>36.8</td><td>128.9</td><td></td></tr><tr><td>28</td><td>92</td><td>137.0</td><td>51.3</td><td>136.9</td><td></td></tr><tr><td>29</td><td>80</td><td>137.3</td><td>48.4</td><td>133.6</td><td></td></tr><tr><td>30</td><td>91</td><td>141.1</td><td>49.8</td><td>125.3</td><td></td></tr><tr><td>31</td><td>103</td><td>142.0</td><td>50.9</td><td>137.4</td><td></td></tr><tr><td>32</td><td>101</td><td>142.0</td><td>51.3</td><td>132.7</td><td></td></tr><tr><td>33</td><td>95</td><td>135.2</td><td>56.5</td><td>126.8</td><td></td></tr><tr><td>34</td><td>102</td><td>137.9</td><td>44.0</td><td>136.0</td><td></td></tr><tr><td>35</td><td>121</td><td>141.5</td><td>49.4</td><td>136.1</td><td></td></tr><tr><td>36</td><td>102</td><td>135.6</td><td>45.7</td><td>130.4</td><td></td></tr><tr><td>37</td><td>99</td><td>134.2</td><td>48.4</td><td>129.0</td><td></td></tr><tr><td>38</td><td>94</td><td>134.7</td><td>50.7</td><td>121.7</td><td></td></tr><tr><td>39</td><td>59</td><td>137.6</td><td>44.6</td><td>144.8</td><td></td></tr><tr><td>40</td><td>59</td><td>151.9</td><td>52.0</td><td>143.3</td><td></td></tr></table>
0cfbb1128c0d11c4228565b90fc8e5cd820837c3a82461feb0150c9194a86eed.png
simple
<table><tr><td>Independent variables </td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>Health-related risk factors </td><td> </td><td> </td><td> </td></tr><tr><td> Medical conditions (index)</td><td>&#8722;0.134<sup>***</sup></td><td>&#8722;0.052<sup>***</sup></td><td>&#8722;0.036<sup>*</sup></td></tr><tr><td> Mobility difficulties (index)</td><td>&#8722;0.273<sup>***</sup></td><td>&#8722;0.115<sup>***</sup></td><td>&#8722;0.079<sup>***</sup></td></tr><tr><td> Activity limitations (index)</td><td>&#8722;0.504<sup>***</sup></td><td>&#8722;0.196<sup>***</sup></td><td>&#8722;0.168<sup>***</sup></td></tr><tr><td>Sociodemographic variables </td><td> </td><td> </td><td> </td></tr><tr><td> Age (cont.)</td><td> </td><td> </td><td>&#8722;0.104<sup>***</sup></td></tr><tr><td> Language: Swedish (ref. Finnish and others)</td><td> </td><td> </td><td>0.068<sup>***</sup></td></tr><tr><td> Gender: female (ref. male)</td><td> </td><td> </td><td>0.056<sup>***</sup></td></tr><tr><td> Civil status: partnership (ref. single)</td><td> </td><td> </td><td>0.052<sup>***</sup></td></tr><tr><td> Income: high (ref. low)</td><td> </td><td> </td><td>0.062<sup>***</sup></td></tr><tr><td> Education: high (ref. low education)</td><td> </td><td> </td><td>0.083<sup>***</sup></td></tr><tr><td> Country: Sweden (ref. Finland)</td><td> </td><td> </td><td>&#8722;0.015</td></tr><tr><td><i>n</i></td><td> </td><td>5435</td><td>5435</td></tr><tr><td>Adjusted <i>R</i> square</td><td> </td><td>0.071</td><td>0.101</td></tr></table>
7e4f19c69f0c9d6c0553125eeb3ff5dfe8abe98a22d45c84cc82894331384840.png
simple
<table><tr><td> </td><td> </td><td>&#946;</td><td>95% CI</td><td>p value</td></tr><tr><td>Intercept</td><td> </td><td>-4.64</td><td>-8.93; -0.35</td><td> </td></tr><tr><td>Group (Reference: controls)</td><td>NSCLC</td><td>1.63</td><td>0.75; 2.51</td><td>0.0004</td></tr><tr><td>Gender (Reference: male)</td><td>Female</td><td>0.22</td><td>-0.66; 1.10</td><td>0.6210</td></tr><tr><td>Age</td><td>[10 years]</td><td>0.45</td><td>-0.10; 1.00</td><td>0.1058</td></tr><tr><td>Smoking status (Reference: never)</td><td>Ever</td><td>-0.42</td><td>-1.94; 1.10</td><td>0.5848</td></tr></table>
6471c54377e01fec4851589384c90e5906a1286843c84f13feadbfa38306a274.png
complex
<table><tr><td>Test Type</td><td colspan="2">5-Option Version (n = 25)</td><td colspan="2">2-Option Version (n = 37)</td></tr><tr><td></td><td>Without OPC</td><td>With OPC*</td><td>Without OPC</td><td>With OPC**</td></tr><tr><td>FOBT</td><td>21%</td><td>17%</td><td>32%</td><td>54%</td></tr><tr><td>Sigmoidoscopy</td><td>4%</td><td>8%</td><td>-</td><td>-</td></tr><tr><td>FOBT &amp; Sigmoidoscopy</td><td>21%</td><td>21%</td><td>-</td><td>-</td></tr><tr><td>Colonoscopy</td><td>46%</td><td>42%</td><td>68%</td><td>41%</td></tr><tr><td>Barium Enema</td><td>4%</td><td>8%</td><td>-</td><td>-</td></tr><tr><td>No Screening</td><td>4%</td><td>4%</td><td>-</td><td>5%</td></tr></table>
749c2383854fa486ed84ba2a24a7ea56c17764ddf9e53fe7f48d94e48d768969.png
complex
<table><tr><td rowspan="2">Parameter</td><td colspan="2">GM (CV %)<sup>a</sup></td><td colspan="2">GMR (90% CI)<sup>a</sup></td></tr><tr><td>Pre-moringa</td><td>Post-moringa</td><td>Post/Pre</td><td>P</td></tr><tr><td>AUC<sub>0&#8211;12h</sub> (h*&#956;g/mL)</td><td>94.17 (25.24)</td><td>100.44 (27.65)</td><td>1.07 (1.00&#8211;1.14)</td><td>0.131</td></tr><tr><td>C<sub>12h</sub> (&#956;g/mL)</td><td>7.30 (25.85)</td><td>7.55 (28.56)</td><td>1.03 (0.92&#8211;1.16)</td><td>0.702</td></tr><tr><td>C<sub>max,ss</sub> (&#956;g/mL)</td><td>9.92 (26.93)</td><td>10.57 (29.62)</td><td>1.06 (0.98&#8211;1.16)</td><td>0.261</td></tr></table>
87bbafb3dfa85ac171b69aa1149c1c17bb3258f81f571c92f9f6138b1e6a7b26.png
complex
<table><tr><td rowspan="2"> </td><td>Overall</td><td colspan="2">Chronic kidney disease at baseline</td><td rowspan="2"><i>p</i> values</td></tr><tr><td>(<i>n</i> = 162)</td><td>Present (<i>n</i> = 25)</td><td>Absent (<i>n</i> = 137)</td></tr><tr><td>Male sex (<i>n</i>, %)</td><td>89, 55</td><td>12, 48</td><td>77, 56</td><td>0.45</td></tr><tr><td>Smokers (<i>n</i>, %)</td><td>53, 33</td><td>6, 24</td><td>47, 3</td><td>0.30</td></tr><tr><td>Age (years)</td><td>62 &#177; 10</td><td>69 &#177; 9</td><td>61 &#177; 10</td><td>0.000</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>24.2 &#177; 3.7</td><td>25.3 &#177; 4.0</td><td>24.0 &#177; 3.6</td><td>0.10</td></tr><tr><td>Waist circumference (cm)</td><td>87.0 &#177; 10.0</td><td>88.8 &#177; 7.7</td><td>86.7 &#177; 10.3</td><td>0.35</td></tr><tr><td>Duration of diabetes (years)</td><td>9.7 &#177; 7.2</td><td>12.8 &#177; 8.0</td><td>9.1 &#177; 7.0</td><td>0.02</td></tr><tr><td>Treatment of diabetes; diet/OHA/insulin (<i>n</i>, %)</td><td>53/81/28, 33/50/17</td><td>4/14/7, 16/56/28</td><td>49/67/21, 36/49/15</td><td>0.10</td></tr><tr><td>Hypertension; CCB/RASi/diuretics (<i>n</i>, %)</td><td>56/68/7, 35/42/4</td><td>18/17/5, 72/68/20</td><td>38/51/2, 28/37/1</td><td>0.000</td></tr><tr><td>HbA1c (%)</td><td>7.0 &#177; 0.8</td><td>7.2 &#177; 0.8</td><td>7.0 &#177; 0.9</td><td>0.25</td></tr><tr><td>Fasting PG (mg/dL)</td><td>125 &#177; 23</td><td>125 &#177; 24</td><td>126 &#177; 22</td><td>0.86</td></tr><tr><td>Postbreakfast PG (mg/dL)</td><td>154 &#177; 48</td><td>162 &#177; 51</td><td>152 &#177; 48</td><td>0.37</td></tr><tr><td>CV-HbA1c (%)</td><td>6.7 &#177; 5.7</td><td>6.8 &#177; 4.5</td><td>6.7 &#177; 5.9</td><td>0.96</td></tr><tr><td>Total cholesterol (mg/dL)</td><td>188 &#177; 21</td><td>178 &#177; 26</td><td>190 &#177; 20</td><td>0.012</td></tr><tr><td>LDL cholesterol (mg/dL)</td><td>112 &#177; 22</td><td>104 &#177; 24</td><td>113 &#177; 22</td><td>0.06</td></tr><tr><td>HDL cholesterol (mg/dL)</td><td>55 &#177; 15</td><td>50 &#177; 12</td><td>56 &#177; 16</td><td>0.06</td></tr><tr><td>Fasting TG (mg/dL)</td><td>114 &#177; 51</td><td>132 &#177; 73</td><td>111 &#177; 45</td><td>0.06</td></tr><tr><td>Postbreakfast TG (mg/dL)</td><td>145 &#177; 62</td><td>167 &#177; 80</td><td>141 &#177; 57</td><td>0.06</td></tr><tr><td>Serum creatinine (mg/dL)</td><td>0.8 &#177; 0.2</td><td>1.0 &#177; 0.3</td><td>0.7 &#177; 0.1</td><td>0.000</td></tr><tr><td>eGFR (mL/min/1.73 m<sup>2</sup>)</td><td>76 &#177; 16</td><td>51 &#177; 9</td><td>80 &#177; 13</td><td>0.000</td></tr><tr><td> &#916;eGFR (mL/min/1.73 m<sup>2</sup>/year)</td><td>&#8722;1.1 &#177; 2.9</td><td>&#8722;1.2 &#177; 2.4</td><td>&#8722;1.1 &#177; 3.0</td><td>0.93</td></tr><tr><td>Uric acid (mg/dL)</td><td>5.2 &#177; 1.3</td><td>5.7 &#177; 1.3</td><td>5.1 &#177; 1.2</td><td>0.03</td></tr><tr><td>Systolic BP (mmHg)</td><td>128 &#177; 12</td><td>131 &#177; 12</td><td>128 &#177; 12</td><td>0.20</td></tr><tr><td>CV-systolic BP (%)</td><td>8.1 &#177; 2.2</td><td>8.4 &#177; 2.1</td><td>8.0 &#177; 2.2</td><td>0.41</td></tr><tr><td>Diastolic BP (mmHg)</td><td>72 &#177; 6</td><td>69 &#177; 5</td><td>73 &#177; 7</td><td>0.02</td></tr><tr><td>Urinary ACR (mg/g)</td><td>86 &#177; 327</td><td>233 &#177; 531</td><td>59 &#177; 268</td><td>0.014</td></tr><tr><td>log ACR</td><td>1.3 &#177; 0.6</td><td>1.7 &#177; 0.8</td><td>1.2 &#177; 0.5</td><td>0.001</td></tr><tr><td>Leucocyte count (10<sup>3</sup>/<i>&#956;</i>L)</td><td>5.8 &#177; 1.5</td><td>6.1 &#177; 1.3</td><td>5.7 &#177; 1.5</td><td>0.19</td></tr><tr><td>Maximum IMT (mm)</td><td>1.0 &#177; 0.3</td><td>1.1 &#177; 0.4</td><td>1.0 &#177; 0.3</td><td>0.14</td></tr><tr><td>Mean IMT (mm)</td><td>0.8 &#177; 0.2</td><td>0.9 &#177; 0.2</td><td>0.8 &#177; 0.2</td><td>0.26</td></tr><tr><td>ACR &#8805; 30 mg/g (<i>n</i>, %)</td><td>53, 33</td><td>12, 48</td><td>41, 30</td><td>0.08</td></tr></table>
eb0fec0d298d5fd43507153ecf98b1fd1ca07c70cef92bc01ce3c3c0e850cbff.png
simple
<table><tr><td>Hierarchy Depth</td><td>PPStream</td><td>PPTV</td><td>QQLive</td><td>PPfilm</td><td>UUSee</td><td>All</td></tr><tr><td>1</td><td>19.12%</td><td>3.20%</td><td>15.95%</td><td>8.34%</td><td>3.25%</td><td>14.72%</td></tr><tr><td>2</td><td>80.87%</td><td>44.69%</td><td>9.34%</td><td>43.35%</td><td>85.64%</td><td>50.76%</td></tr><tr><td>3</td><td>0.014%</td><td>52.11%</td><td>17.50%</td><td>48.31%</td><td>11.11%</td><td>27.42%</td></tr><tr><td>4</td><td>0.00%</td><td>0.004%</td><td>57.22%</td><td>0.003%</td><td>0.00%</td><td>7.09%</td></tr><tr><td>5</td><td>0.00%</td><td>0.00%</td><td>0.0003%</td><td>0.00%</td><td>0.00%</td><td>0.002%</td></tr></table>
05c5f9d87b014294bbd3514d7ce6736f27ea8616d6b8830bc356c316527d48b7.png
complex
<table><tr><td rowspan="2">Time from onset of illness </td><td rowspan="2">Signs/symptoms</td><td rowspan="2">Drug exposure </td><td colspan="5">Laboratory values</td></tr><tr><td>ALT</td><td>ALP</td><td>Total bilirubin</td><td>Direct bilirubin</td><td>Misc.</td></tr><tr><td>&#8722;5</td><td>Sore throat</td><td>Amoxicillin started</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>0</td><td>Fever, anorexia, dysphagia, neck swelling, and cervical lymphadenopathy</td><td>Ceftriaxone and vancomycin started </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3&#8211;5</td><td>Worsening of neck swelling</td><td>Ceftriaxone and vancomycin discontinued, and ampicillin/sulbactam and steroid started</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>5&#8211;10</td><td>Diarrhea</td><td>Ampicillin/sulbactam and steroid discontinued, and clindamycin and probiotics started</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>10</td><td>Fever, headache, dizziness, chest pain on coughing, and dark urine. Hepatosplenomegaly, RUQ tenderness</td><td>Clindamycin switched to ampicillin/sulbactam</td><td>406</td><td>404</td><td>3.0</td><td>2.7</td><td> </td></tr><tr><td>16&#8211;23</td><td>Generalized maculopapular rash and pruritus </td><td>Ampicillin/sulbactam</td><td>152</td><td>737</td><td>8.8</td><td> </td><td> </td></tr><tr><td>25&#8211;30</td><td>Abdominal pain, vomiting. Hepatomegaly</td><td>Ampicillin/sulbactam</td><td>124</td><td>780</td><td>9.9</td><td> </td><td>AST 130</td></tr><tr><td>48</td><td>Chest pain, fatigue, pruritus, acholic stools, and jaundice</td><td> </td><td>138</td><td>713</td><td>13.4</td><td>8.8</td><td>Cholesterol 1044, GGT 347,</td></tr><tr><td>53</td><td>Increasing pruritus, anorexia</td><td> </td><td>117</td><td>651</td><td>12.7</td><td>8.5</td><td>GGT 294</td></tr><tr><td>67</td><td>Anorexia, pruritus</td><td> </td><td>48</td><td>493</td><td>12.6</td><td>8.7</td><td>GGT 77</td></tr><tr><td>83</td><td>Anorexia</td><td> </td><td>83</td><td>497</td><td>8.3</td><td>5.5</td><td>GGT 273</td></tr><tr><td>111</td><td>No anorexia</td><td> </td><td>51</td><td>670</td><td>2.3</td><td>1.2</td><td>GGT 507</td></tr></table>
3bdfcfeaa81caae9b2b951164302a3b2746c092b81fcdccae3f0ab94d39f469c.png
simple
<table><tr><td>Inclusion criteria</td><td>Exclusion criteria</td></tr><tr><td>Original research articles referring to noninvasive modalities or minimally invasive techniques to accelerate orthodontic tooth movementAnimal studies</td><td>Randomized clinical trialsArticles dealing with highly invasive proceduresArticles referring to use of biochemical or drugs to accelerate tooth movementMicroimplants or frictionless brackets as a modality to reduce treatment duration Reviews, interviews, and discussions</td></tr></table>
5130f090a192def49d78284176a0f51004408773afa9cda306687f054fcd343f.png
simple
<table><tr><td></td><td>GP*</td><td>Combinations*</td></tr><tr><td></td><td>OR (95% CI)<sup>&#8224;</sup></td><td>OR (95% CI)<sup>&#8224;</sup></td></tr><tr><td>Age</td><td>1.00 (0.99-1.02)</td><td>1.00 (0.98-1.02)</td></tr><tr><td>Man</td><td>1.00</td><td>1.00</td></tr><tr><td>Woman</td><td>1.24 (0.84-1.85)</td><td>1.17 (0.83-1.65)</td></tr><tr><td>Normal weight (BMI &lt; 25 kg/m<sup>2</sup>)</td><td>1.00</td><td>1.00</td></tr><tr><td>Overweight (BMI 25-29.99 kg/m<sup>2</sup>)</td><td>1.35 (0.81-2.26)</td><td>1.71 (1.09-2.68)</td></tr><tr><td>Obese (BMI &#8805; 30 kg/m<sup>2</sup>)</td><td>1.72 (1.00-2.93)</td><td>1.62 (1.00-2.62)</td></tr><tr><td>Lowest quintile of deprivation</td><td>1.00</td><td>1.00</td></tr><tr><td>Highest quintile of deprivation</td><td>1.00 (0.57-1.74)</td><td>0.98 (0.59-1.61)</td></tr><tr><td>Living in rural areas</td><td>1.00</td><td>1.00</td></tr><tr><td>Living in urban areas</td><td>2.40 (1.14-5.04)</td><td>1.18 (0.71-1.97)</td></tr><tr><td>Pain in both hips and knees</td><td>1.00</td><td>1.00</td></tr><tr><td>Pain in hips only</td><td>0.96 (0.56-1.66)</td><td>0.96 (0.59-1.57)</td></tr><tr><td>Pain in knees only</td><td>1.03 (0.67-1.59)</td><td>1.17 (0.80-1.72)</td></tr><tr><td>Pain severity</td><td>1.28 (1.13-1.44)</td><td>1.48 (1.34-1.64)</td></tr><tr><td>Not anxious/depressed</td><td>1.00</td><td>1.00</td></tr><tr><td>Anxious/depressed</td><td>0.88 (0.58-1.33)</td><td>1.04 (0.73-1.49)</td></tr><tr><td>No mobility problems</td><td>1.00</td><td>1.00</td></tr><tr><td>Mobility problems</td><td>2.62 (1.64-4.17)</td><td>2.77 (1.83-4.20)</td></tr><tr><td>0-1 other health problems</td><td>1.00</td><td>1.00</td></tr><tr><td>2 health problem areas</td><td>1.60 (0.84-3.05)</td><td>1.31 (0.76-2.28)</td></tr><tr><td>3 health problem areas</td><td>1.76 (0.93-3.34)</td><td>1.15 (0.66-2.01)</td></tr><tr><td>4 or more health problem areas</td><td>1.28 (0.66-2.48)</td><td>1.26 (0.73-2.18)</td></tr></table>
29773f3ebdf2e68650a53d3ab35377a03a1b0e3cef305a6e22fa0a47673ad54c.png
complex
<table><tr><td rowspan="2">Area</td><td rowspan="2">Parameter estimate (SE)</td><td rowspan="2"><i>t</i>&#8208;Value (<i>P</i>&#8208;value) for parameter difference from zero</td><td colspan="5"><i>t</i>&#8208;Values (<i>P</i>&#8208;values) for differences of least squares means</td></tr><tr><td>Garbage</td><td>Light</td><td>Lawn</td><td>Other modified</td><td>Natural</td></tr><tr><td>Garbage</td><td>2.92 (0.52)</td><td>5.61 (&lt;0.0001)</td><td></td><td>2.66 (0.08)</td><td>4.34 (&lt;0.01)b</td><td>4.11 (&lt;0.01)b</td><td>5.61 (&lt;0.0001)b</td></tr><tr><td>Under lights</td><td>1.47 (0.60)</td><td>2.46 (0.01)</td><td></td><td></td><td>0.96 (0.87)</td><td>1.37 (0.65)</td><td>2.46 (0.12)</td></tr><tr><td>Lawn</td><td>0.89 (0.58)</td><td>1.54 (0.13)</td><td></td><td></td><td></td><td>0.48 (0.99)</td><td>1.54 (0.54)</td></tr><tr><td>Other modified</td><td>0.60 (0.63)</td><td>0.94 (0.35)</td><td></td><td></td><td></td><td></td><td>0.94 (0.88)</td></tr><tr><td>Natural</td><td>0a</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
35ad47d8f26aba7b94956169dc60f9b995ee7e5c90087a56afcae4a214be9a89.png
simple
<table><tr><td>Sample Name</td><td>Raw Reads</td><td>Clean Reads</td><td>Clean Bases</td><td>Total Mapped</td><td>Error Rate (%)</td><td>Q20 (%)</td><td>Q30 (%)</td><td>GC Content (%)</td></tr><tr><td>O<sub>2</sub>-treated_1</td><td>12,984,364</td><td>12,920,255</td><td>0.65 G</td><td>12,360,505 (95.67%)</td><td>0.01</td><td>97.9</td><td>94.07</td><td>43.13</td></tr><tr><td>O<sub>2</sub>-treated_2</td><td>11,192,761</td><td>11,131,963</td><td>0.56 G</td><td>10,740,908 (96.49%)</td><td>0.01</td><td>98.84</td><td>96.07</td><td>43.38</td></tr><tr><td>HCl-treated_1</td><td>13,670,896</td><td>13,598,605</td><td>0.68 G</td><td>13,068,581 (96.1%)</td><td>0.01</td><td>97.92</td><td>94.13</td><td>43.44</td></tr><tr><td>HCl-treated_2</td><td>13,595,227</td><td>13,514,169</td><td>0.68 G</td><td>12,993,548 (96.15%)</td><td>0.01</td><td>98.64</td><td>95.87</td><td>45.03</td></tr><tr><td>Non-treated_1</td><td>12,361,440</td><td>12,313,326</td><td>0.62 G</td><td>11,827,559 (96.05%)</td><td>0.01</td><td>97.91</td><td>94.12</td><td>43.15</td></tr><tr><td>Non-treated_2</td><td>12,559,734</td><td>12,506,248</td><td>0.63 G</td><td>11,993,516 (95.9%)</td><td>0.01</td><td>98.16</td><td>94.66</td><td>43.5</td></tr></table>
363d976632a8a3944b3e7d520bd40ea1df759832410db6e6f39b0b4b2571935d.png
simple
<table><tr><td>Locus</td><td>Primer sequences (5<sup>&#8242;</sup>&#8211;3<sup>&#8242;</sup>)</td><td>Primer sequences (5<sup>&#8242;</sup>&#8211;3<sup>&#8242;</sup>)</td></tr><tr><td>b50</td><td>F: AACAATCCAGGAGTGGCAATC</td><td>R: ACAAGCGAAGATCGTCTCATC</td></tr><tr><td>b35</td><td>F: CGTTCAGTCACCAGCAAGG</td><td>R: GAGGGAAGCAGGGAGAGC</td></tr><tr><td>b38</td><td>F: TAATCCCTCAATGGCTCTTTTC</td><td>R: GAGAAGGATACGAATTGACAGG</td></tr><tr><td>b40</td><td>F:TGTATAGAACTGAGTAAATGATTG</td><td>R: CAACTTTCTTAAACCACTTTCG</td></tr><tr><td>b43</td><td>F: CGAGCCTTCTTCTTCTTCTGG</td><td>R: GCAAGCAATACGGACAGTAGG</td></tr><tr><td>c03</td><td>F:CGTGAAAATAGTGATATGTGTG</td><td>R: ACTGTAACAATCAAGAAGAAACC</td></tr><tr><td>c07</td><td>F:GCCACAGCCGAGGAAGAG</td><td>R: TCTCATCACCACCACCTTAGG</td></tr><tr><td>b27</td><td>F: AGCCAGGTTCCAGAAGTCC</td><td>R: CATAATCACAAAGTCTCGGTTCC</td></tr><tr><td>b28</td><td>F: TCCCACCACGGACTACTG</td><td>R: AACCACCATCATCATCATCATC</td></tr><tr><td>b11</td><td>F: GCGGAGGCTTAATTTGCTTTG</td><td>R: ACTCAATACATACACGGCACTAG</td></tr><tr><td>b16</td><td>F: ACCTCTACGGACCTCTTCTTC</td><td>R: CATAACATAACATGACACACAAGC</td></tr><tr><td>b24</td><td>F: GAGCCAGAGCCAGGTTCC</td><td>R: ACAAAGTCTCGGTTCCTTACAC</td></tr><tr><td>b34</td><td>AATAGAATGTGGAGGCGATAGAG</td><td>R: AAACCATAAATCAACTACCGAACC</td></tr><tr><td>b64</td><td>F: CTTGAGATACAGCCTTCCATTAG</td><td>R: CACACCTCGCTTCCCTTG</td></tr><tr><td>c17</td><td>F:GAAACTATTTCCACCAACAAAG</td><td>R: ACACACATTCCTACACACC</td></tr><tr><td>b57</td><td>F: CGGATATGGTGGAGGTTATGC</td><td>R: CAGAACGACGACGACGAC</td></tr><tr><td>b65</td><td>F: ACGAACCACAACACAGAGAG</td><td>R: ACGAGGGAACACCAGAGAG</td></tr><tr><td>c18</td><td>F:AAGCCGAGCGTGAAGAAG</td><td>R: ACACACAGAAAGAACACAAGAC</td></tr><tr><td>b53</td><td>F: GGCTCAAGTTTGCTCATAGATTC</td><td>R: CGGCTTCGCTTTAGGATTTG</td></tr><tr><td>b56</td><td>F: CGGTCTGTGGATACGAATGG</td><td>R: GACGACGACGACGATGATG</td></tr><tr><td>c10</td><td>F:AGTGCGGAGATAACTGTTC</td><td>R: GGCTACTTTATTCTAAACCAAAC</td></tr></table>
63f89033a552f02f8685503067f548596aaa8a96e04c7c9cc45b08a6cbb21777.png
complex
<table><tr><td rowspan="2">Phases</td><td rowspan="2">Contacted</td><td rowspan="2">Screening1<sup>a</sup></td><td rowspan="2">Screening2<sup>b</sup></td><td rowspan="2">Screening3<sup>c</sup></td><td colspan="2">Successfully recruited</td></tr><tr><td>IG</td><td>CG</td></tr><tr><td>Run-in</td><td>214</td><td>184 (86)</td><td>106 (50)</td><td>109 (51)</td><td>50 (23)</td><td>50 (23)</td></tr><tr><td>Main</td><td>488</td><td>378 (78)</td><td>306 (63)</td><td>300 (62)</td><td>140 (29)</td><td>140 (29)</td></tr><tr><td>TOTAL</td><td>702</td><td>562 (80)</td><td>412 (59)</td><td>409 (58)</td><td>190 (27)</td><td>190 (27)</td></tr></table>
7d49e2268b26478bfed42bd398b7a0c5041b1d68e4a963f6a29c309beba62d94.png
complex
<table><tr><td colspan="3">Study characteristics</td><td colspan="2">WBC</td><td colspan="2">Monocytes</td><td colspan="2">Neutrophils</td><td colspan="2">Lymphocytes</td><td colspan="2">Neutrophil to lymphocyte ratio</td><td>Reference</td></tr><tr><td>Population</td><td>FU</td><td>Size (<i>n</i>)</td><td>Risk [95% CI]</td><td><i>p</i></td><td>Risk [95% CI]</td><td><i>p</i></td><td>Risk [95% CI]</td><td><i>p</i></td><td>Risk [95% CI]</td><td><i>p</i></td><td>Risk [95% CI]</td><td><i>p</i></td><td></td></tr><tr><td>PCI</td><td>&lt;1</td><td>309</td><td>1.2 [1.0&#8211;1.3]<sup>b</sup></td><td>*</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(27)</td></tr><tr><td>PCI</td><td>1&#8211;6</td><td>1,425</td><td>4.8 [1.3&#8211;16.8]</td><td>n.s.</td><td>1.7 [1.0&#8211;2.9]</td><td>n.s.</td><td>5.7 [1.6&#8211;19.6]</td><td>n.s.</td><td></td><td></td><td>5.6 [1.6&#8211;19.8]</td><td>**</td><td>(40)</td></tr><tr><td>PCI</td><td>&gt;6&#8211;36</td><td>83</td><td>14.7 [2.7&#8211;80.7]</td><td>**</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(29)</td></tr><tr><td>UAP/NSTEMI</td><td>&gt;6&#8211;36</td><td>280</td><td>1.4 [0.6&#8211;2.9]</td><td>n.s.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(41)</td></tr><tr><td>CAD</td><td>&gt;6&#8211;36</td><td>1,246</td><td>2.0 [1.3&#8211;3.1]</td><td>**</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(36)</td></tr><tr><td>CAD</td><td>&gt;6&#8211;36</td><td>422</td><td>5.3 [1.2&#8211;24.1]</td><td>n.s.</td><td>6.4 [1.4&#8211;28.8]</td><td>n.s.</td><td>5.5 [1.2&#8211;24.7]<sup>c</sup></td><td>n.s.</td><td>4.2 [1.4&#8211;12.4]<sup>a</sup></td><td>n.s.</td><td>8.1 [1.4&#8211;46.6]</td><td>*</td><td>(38)</td></tr><tr><td>PCI</td><td>&gt;6&#8211;36</td><td>1,046</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1.9 [1.3&#8211;3.0]</td><td>*</td><td>(44)</td></tr><tr><td>UAP/NSTEMI</td><td>&gt;36</td><td>275</td><td>1.7 [1.1&#8211;2.5]</td><td>*</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(34)</td></tr><tr><td>PCI</td><td>&gt;36</td><td>1,425</td><td>1.7 [1.0&#8211;2.7]</td><td>n.s.</td><td>2.0 [1.2&#8211;3.4]</td><td>*</td><td>2.0 [1.2&#8211;3.3]</td><td>n.s.</td><td>0.6 [0.4&#8211;0.9]</td><td>n.s.</td><td>3.0 [1.8&#8211;5.0]</td><td>***</td><td>(40)</td></tr></table>
6488f2e501a3a1df9bc01288356d66ce53f0f5712ea09ff13365ccffb7c848a8.png
simple
<table><tr><td>Second-level category</td><td><i>n</i> (%)</td></tr><tr><td>b140 attention functions</td><td>149 (85)</td></tr><tr><td>b130 energy and drive functions</td><td>127 (73)</td></tr><tr><td>b147 psychomotor functions</td><td>124 (71)</td></tr><tr><td>b760 control of voluntary movement functions</td><td>114 (65)</td></tr><tr><td>b164 higher-level cognitive functions</td><td>106 (61)</td></tr><tr><td>b152 emotional functions</td><td>90 (51)</td></tr><tr><td>b126 temperament and personality functions</td><td>64 (37)</td></tr><tr><td>b125 dispositions and intra-personal functions</td><td>58 (33)</td></tr><tr><td>b144 memory functions</td><td>55 (31)</td></tr><tr><td>b117 intellectual functions</td><td>31 (18)</td></tr><tr><td>b156 perceptual functions</td><td>31 (18)</td></tr><tr><td>b134 sleep functions</td><td>30 (17)</td></tr><tr><td>b180 experience of self and time functions</td><td>26 (15)</td></tr><tr><td>b235 vestibular functions</td><td>19 (11)</td></tr><tr><td>b735 muscle tone functions</td><td>15 (9)</td></tr><tr><td>b260 proprioceptive functions</td><td>14 (8)</td></tr><tr><td>b160 thought functions</td><td>12 (7)</td></tr><tr><td>b210 seeing functions</td><td>12 (7)</td></tr><tr><td>b230 hearing functions</td><td>11 (6)</td></tr><tr><td>b110 consciousness functions</td><td>10 (6)</td></tr><tr><td>b122 global psychosocial functions</td><td>10 (6)</td></tr><tr><td>b163 basic cognitive functions</td><td>10 (6)</td></tr><tr><td>b114 orientation functions</td><td>9 (5)</td></tr><tr><td>b167 mental functions of language</td><td>9 (5)</td></tr><tr><td>b280 sensation of pain</td><td>9 (5)</td></tr><tr><td>b330 fluency and rhythm of speech functions</td><td>9 (5)</td></tr><tr><td>b765 involuntary movement functions</td><td>9 (5)</td></tr><tr><td>b176 mental function of sequencing complex movements</td><td>8 (5)</td></tr><tr><td>b265 touch function</td><td>8 (5)</td></tr><tr><td>b270 sensory functions related to temperature and other stimuli</td><td>8 (5)</td></tr></table>
51ea889d2dca48d108499386ab8c663f675f9afc919ae406eee77d8c8b2dd48e.png
simple
<table><tr><td></td><td>Total</td><td>Asp299Asp</td><td>Asp299Gly</td><td><i>P</i></td></tr><tr><td>n (%)</td><td>138</td><td>125 (90.6)</td><td>13 (9.4)</td><td></td></tr><tr><td> Oro-Hypopharyngeal SCC; n (%)</td><td>37</td><td>34 (91.9)</td><td>3 (8.1)</td><td>0.76</td></tr><tr><td> Laryngeal SCC; n (%)</td><td>101</td><td>90 (89.1)</td><td>11 (10.9)</td><td></td></tr><tr><td>Mean age &#177; SD [years]</td><td>61 &#177; 10</td><td>60 &#177; 10</td><td>63 &#177; 13</td><td>0.66</td></tr><tr><td>Median follow up [months] (range)<sup>#</sup></td><td>50 (0-129)</td><td>52 (0-129)</td><td>42 (8-98)</td><td>0.37</td></tr><tr><td>Sex (male/female); n</td><td>119/19</td><td>106/19</td><td>13/0</td><td>0.21</td></tr><tr><td>Smoking; n (%)</td><td>124 (89.8)</td><td>112 (89.6)</td><td>12 (92.3)</td><td>1.00</td></tr><tr><td>Mean pack years &#177; SD</td><td>45 &#177; 25</td><td>45 &#177; 24.6</td><td>50 &#177; 29.6</td><td>0.62</td></tr><tr><td>Primary therapy</td><td></td><td></td><td></td><td>0.02</td></tr><tr><td> Surgery alone; n (%)</td><td>61</td><td>57 (45.6)</td><td>4 (30.8)</td><td></td></tr><tr><td> Surgery + RCT<sup>&#167;</sup>; n (%)</td><td>54</td><td>51 (40.8)</td><td>3 (23.1)</td><td></td></tr><tr><td> Primary RCT<sup>&#167;</sup>; n (%)</td><td>23</td><td>17 (13.6)</td><td>6 (46.1)</td><td></td></tr><tr><td>AJCC stage</td><td></td><td></td><td></td><td>0.53</td></tr><tr><td> I; n (%)</td><td>25</td><td>22 (17.6)</td><td>3 (23.1)</td><td></td></tr><tr><td> II; n (%)</td><td>33</td><td>30 (24.0)</td><td>3 (23.1)</td><td></td></tr><tr><td> III; n (%)</td><td>25</td><td>22 (17.6)</td><td>3 (23.1)</td><td></td></tr><tr><td> IVA; n (%)</td><td>50</td><td>47 (37.6)</td><td>3 (23.1)</td><td></td></tr><tr><td> IVB; n (%)</td><td>3</td><td>2 (1.6)</td><td>1 (7.6)</td><td></td></tr><tr><td> IVC; n (%)</td><td>2</td><td>2 (1.6)</td><td>0 (0.0)</td><td></td></tr><tr><td>Grade</td><td></td><td></td><td></td><td>0.32</td></tr><tr><td> 1; n (%)</td><td>9</td><td>7 (5.6)</td><td>2 (15.4)</td><td></td></tr><tr><td> 2; n (%)</td><td>96</td><td>87 (69.6)</td><td>9 (69.2)</td><td></td></tr><tr><td> 3-4; n (%)</td><td>25</td><td>23 (18.4)</td><td>2 (15.4)</td><td></td></tr></table>
b99ce6eb8705264f99054dfcf90aa2d3c39777514f947d785aa075fd882c9f97.png
simple
<table><tr><td></td><td>Total number</td><td>Gleason grade group 1</td><td>Gleason grade group 2</td><td>Gleason grade group 3</td><td>Gleason grade group 4</td><td>Gleason grade group 5</td></tr><tr><td>N&#176; of primary tumors</td><td>60</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td></tr><tr><td>N&#176; of CD44v8-10</td><td>24</td><td>3</td><td>3</td><td>5</td><td>6</td><td>5</td></tr><tr><td>% positive tumors</td><td>40%</td><td>25%</td><td>25%</td><td>42%</td><td>50%</td><td>42%</td></tr></table>
bd7742a7d3779064adfc14e4b139e7b569f157475e12a8cea08d6b89e8a0f695.png
complex
<table><tr><td> </td><td colspan="3">Boys</td><td colspan="3">Girls</td></tr><tr><td> </td><td>Verbal abuse</td><td>Threat of violence</td><td>Physical assault</td><td>Verbal abuse</td><td>Threat of violence</td><td>Physical assault</td></tr><tr><td>Verbal abuse</td><td>1.00</td><td> </td><td> </td><td>1.00</td><td> </td><td> </td></tr><tr><td>Threat of violence</td><td>0.35*</td><td>1.00</td><td> </td><td>0.34*</td><td>1.00</td><td> </td></tr><tr><td>Physical assault</td><td>0.27*</td><td>0.52*</td><td>1.00</td><td>0.23*</td><td>0.36*</td><td>1.00</td></tr></table>
b7ea718770646b4932e6307cfac20073a8426f7429352e9e8e925cdc676b32dd.png
complex
<table><tr><td> </td><td colspan="2">Clinical setting</td></tr><tr><td>Barrier</td><td>HTN &amp; eGFR &#8805; 60 (%)</td><td>HTN &amp; eGFR &lt; 60 (%)</td></tr><tr><td>No impact on management</td><td>37</td><td>24</td></tr><tr><td>Limited time/more urgent patient issues</td><td>25</td><td>20</td></tr><tr><td>Not recommended by guidelines</td><td>25</td><td>11</td></tr><tr><td>Cost</td><td>13</td><td>9</td></tr><tr><td>Poor patient adherence</td><td>5</td><td>5</td></tr></table>
cf6e040c25d10e41e34272078e3617d92b761d5282e65a24591c952a9459fd99.png
complex
<table><tr><td rowspan="2">Progression to PID</td><td rowspan="2">Fraction progressing, % (95% CI)<sup>*</sup></td><td colspan="2">Cumulative incidence of PID after one year, % (95% CI)<sup>&#8224;</sup></td><td rowspan="2">Akaike&#8217;s Information Criterion<sup>&#8225;</sup></td></tr><tr><td>Control group</td><td>Intervention group</td></tr><tr><td><i>Data</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Results from RCT</td><td> </td><td>1.9 (1.2 to 2.9)</td><td>1.3 (0.7 to 2.1)</td><td> </td></tr><tr><td><i>Model</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Immediate progression</td><td>8.3 (5.7 to 11.0)</td><td>1.6 (1.1 to 2.1)</td><td>1.6 (1.1 to 2.1)</td><td>13.3</td></tr><tr><td>Constant progression</td><td>9.9 (6.8 to 13.0)</td><td>1.7 (1.2 to 2.3)</td><td>1.5 (1.0 to 1.9)</td><td>12.1</td></tr><tr><td>Progression at the end</td><td>10.0 (6.8 to 13.1)</td><td>1.7 (1.2 to 2.3)</td><td>1.5 (1.0 to 1.9)</td><td>12.1</td></tr></table>
f4f55eff858fa711c198b313af0ae3362bc9cdf86bf1b148de7bce1b36d65184.png
simple
<table><tr><td>Fc <i>&#947;</i> IIA genotype</td><td>Mild (&lt;8)</td><td>Moderate (8&#8211;18)</td><td>Severe (&gt;18)</td></tr><tr><td>R131/R131 (<i>n</i> = 16)</td><td>2</td><td>4</td><td>10</td></tr><tr><td>R131/H131 (<i>n</i> = 54)</td><td>10</td><td>26</td><td>18</td></tr><tr><td>H131/H131 (<i>n</i> = 10)</td><td>0</td><td>10</td><td>0</td></tr><tr><td>Total (<i>n</i> = 80)</td><td>12 (15%)</td><td>40 (50%)</td><td>28 (35%)</td></tr></table>
75342cb85126a050ee72e37de48b78c49741fff505d659dc45652ff6510d303d.png
simple
<table><tr><td> </td><td>Pharmacologic intervention title: &#8216;Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomized placebo-controlled trial&#8217; [28]</td><td>Non-pharmacologic intervention title: &#8216;Treatment of childhood obesity by retraining eating behaviour: randomized controlled trial&#8217; [29]</td></tr><tr><td>Active ingredients</td><td>Vitamins C and E</td><td>Not reported</td></tr><tr><td>Comparator</td><td>Placebo</td><td>Not reported</td></tr><tr><td>Health condition</td><td>Pre-eclampsia</td><td>Obesity</td></tr><tr><td>Eligibility criteria</td><td>Women with type 1 diabetes</td><td>Children</td></tr><tr><td>Objective</td><td>Prevention of pre-eclampsia</td><td>Retraining eating behaviour</td></tr><tr><td>Trial design</td><td>Randomized controlled trial</td><td>Randomized controlled trial</td></tr></table>
5d2ad6dabb42780197282912c158daacfc5ea514ba920ef57f91090e53add307.png
simple
<table><tr><td>Item</td><td>N-free</td><td>Soybean meal</td><td>Rapeseed meal</td><td>Canola meal</td></tr><tr><td>Ingredients (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Corn starch</td><td>56.50</td><td>44.79</td><td>32.34</td><td>37.94</td></tr><tr><td>Soybean meal (44 %)</td><td>-</td><td>52.24</td><td>-</td><td>-</td></tr><tr><td>Rapeseed meal (35 %)</td><td>-</td><td>-</td><td>65.57</td><td>-</td></tr><tr><td>Canola meal (38 %)</td><td>-</td><td>-</td><td>-</td><td>59.78</td></tr><tr><td>Sucrose</td><td>20.00</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Glucose</td><td>20.00</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Choline chloride (50 %)</td><td>0.05</td><td>0.05</td><td>0.05</td><td>0.05</td></tr><tr><td>TCP</td><td>1.68</td><td>1.13</td><td>0.65</td><td>0.74</td></tr><tr><td>Limestone</td><td>0.62</td><td>0.64</td><td>0.24</td><td>0.34</td></tr><tr><td>Salt</td><td>0.30</td><td>0.30</td><td>0.30</td><td>0.30</td></tr><tr><td>Mineral premix<sup>1</sup></td><td>0.30</td><td>0.30</td><td>0.30</td><td>0.30</td></tr><tr><td>Vitamin premix<sup>2</sup></td><td>0.30</td><td>0.30</td><td>0.30</td><td>0.30</td></tr><tr><td>Chromic oxide</td><td>0.25</td><td>0.25</td><td>0.25</td><td>0.25</td></tr><tr><td>Total</td><td>100.00</td><td>100.00</td><td>100.00</td><td>100.00</td></tr><tr><td>Chemical composition (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>ME (kcal/kg)</td><td>3,509</td><td>3,391</td><td>2,904</td><td>3,125</td></tr><tr><td>CP</td><td>-</td><td>23.00</td><td>23.00</td><td>23.00</td></tr><tr><td>Calcium</td><td>0.70</td><td>0.70</td><td>0.70</td><td>0.70</td></tr><tr><td>Available phosphorus</td><td>0.32</td><td>0.32</td><td>0.32</td><td>0.32</td></tr><tr><td>Lysine</td><td>-</td><td>1.44</td><td>1.31</td><td>1.18</td></tr><tr><td>Met + Cys</td><td>-</td><td>0.66</td><td>1.08</td><td>0.76</td></tr></table>
df6da30263d07dcf79de289521b727b6ee72bde7e7a19ca977e051a820cb180b.png
simple
<table><tr><td>Matrix Mechanical Characteristics that Impact Cell or Tissue Function</td></tr><tr><td>&#8226; Pore size and morphology (Chan et al., 2008); [142]</td></tr><tr><td>&#8226; Elasticity (Janson et al., 2015); [131]</td></tr><tr><td>&#8226; Stiffness (Xia et al., 2017); [143]</td></tr><tr><td>&#8226; Hydration degree (Wu et al., 2006); [140]</td></tr></table>
4bc2eb01b59d8b42609a7836cf86017f695fde75c10a873db745d5b2efc7e79f.png
simple
<table><tr><td>Name</td><td>SNP</td><td>Primer</td><td>Product length (bp)</td><td>Primer sequence (5&#8217;&#8594;3&#8217;)</td></tr><tr><td>rs17576</td><td>A/G</td><td>Forward</td><td></td><td>CAATTCACCCTCCCGCACTC</td></tr><tr><td></td><td></td><td>Reverse</td><td>222</td><td>GGAAGATGAATGGAAACTGG</td></tr><tr><td>rs2250889</td><td>C/G</td><td>Forward</td><td></td><td>GTATTTGTTCAAGGATGGGTG</td></tr><tr><td></td><td></td><td>Reverse</td><td>367</td><td>AGACGTTTCGTGGGTTAT</td></tr></table>
56a613f6f6c150d2996950551efbe510bd69debe377c353c8a2eac15a398f2f9.png
simple
<table><tr><td>Material</td><td>Tested</td><td>Ref.</td></tr><tr><td>Boron nitride, BN</td><td>Tested, in use, high efficiency, low erosion (0.02 mm<sup>3</sup>/C at 300 V)</td><td><sup>131, 139, 140</sup></td></tr><tr><td>Borosil, BN + SiO<sub>2</sub></td><td>Tested, in use, high efficiency, low wear</td><td><sup>131, 141</sup></td></tr><tr><td>Alumina, Al<sub>2</sub>O<sub>3</sub></td><td>Tested, medium efficiency, low erosion (0.01 mm<sup>3</sup>/C at 300 V)</td><td><sup>139, 141</sup></td></tr><tr><td>Silicon carbide, SiC</td><td>Tested, medium efficiency, medium erosion</td><td><sup>131</sup></td></tr><tr><td>Graphite</td><td>Tested, low efficiency, high erosion</td><td><sup>65</sup></td></tr><tr><td>Nanocrystalline diamond</td><td>Tested, high efficiency, low erosion</td><td><sup>131, 142</sup></td></tr><tr><td>CVD diamond</td><td>Tested for wear, lower erosion</td><td><sup>63</sup></td></tr><tr><td>Ultra-BN, uBN</td><td>Tested, high efficiency, very low wear</td><td>New result</td></tr></table>
c31119842d47c98347302fedebfaf033986e95d71efab2ba903c26fb14988379.png
complex
<table><tr><td> </td><td colspan="2">HAZ</td><td colspan="2">WAZ</td></tr><tr><td> </td><td>Coefficient</td><td>Percent of &#8710;</td><td>Coefficient</td><td>Percent of &#8710;</td></tr><tr><td>Raw gap, &#8710;</td><td>.379</td><td>100.00</td><td>.248</td><td>100.00</td></tr><tr><td>Of which:</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Explained</td><td>.234</td><td>61.7</td><td>.164</td><td>66.3</td></tr><tr><td> Unexplained</td><td>.145</td><td>38.3</td><td>.083</td><td>33.7</td></tr></table>
b130b366b6808684e907d159618ab92988b63f3290be4ca18afb6cc3995f277f.png
complex
<table><tr><td>Sub-scale</td><td>Attitudinal items</td><td colspan="2">Surgeon (n=41)</td><td colspan="2">Anaesthetist (n= 33)</td><td colspan="2">Nurse (n=33)</td></tr><tr><td> </td><td> </td><td>Mode</td><td>IQR</td><td>Mode</td><td>IQR</td><td>Mode</td><td>IQR</td></tr><tr><td> </td><td>There is little difference between the surgical checklist at GUH and the WHO surgical checklist.</td><td>3</td><td>2</td><td>1</td><td>3.25</td><td>2</td><td>2.75</td></tr><tr><td>Norms</td><td>The complete checklist is used for every procedure in every theatre at UHG.</td><td>2</td><td>3</td><td>1</td><td>3</td><td>5</td><td>1</td></tr><tr><td> </td><td>The complete checklist is used for every procedure in which I am involved in theatre.</td><td>5</td><td>1.5</td><td>1</td><td>3</td><td>5</td><td>1</td></tr><tr><td> </td><td>When the checklist is being carried out, everyone in theatre stops what they are doing and listens until it is completed.</td><td>1</td><td>3</td><td>1</td><td>1</td><td>1</td><td>1.5</td></tr><tr><td> </td><td>Sometimes sections of the checklist are not completed.*</td><td>4</td><td>2</td><td>4</td><td>2</td><td>4</td><td>1</td></tr><tr><td> </td><td>The individual who signs the checklist personally ensures that the relevant steps have been completed.</td><td>5</td><td>1.5</td><td>4</td><td>2</td><td>4</td><td>1</td></tr><tr><td>Impact on teamwork &amp; safety</td><td>I believe that failing to use the checklist is poor professional practice.</td><td>5</td><td>1</td><td>5</td><td>1</td><td>5</td><td>0</td></tr><tr><td> </td><td>I believe using the checklist reduces the likelihood of human error.</td><td>5</td><td>0.75</td><td>5</td><td>1</td><td>5</td><td>0</td></tr><tr><td> </td><td>I believe using the checklist improves patient safety.</td><td>5</td><td>0.5</td><td>5</td><td>1</td><td>5</td><td>0</td></tr><tr><td> </td><td>I believe using the checklist improves teamwork in theatre.</td><td>5</td><td>1</td><td>5</td><td>1</td><td>5</td><td>1</td></tr><tr><td> </td><td>The use of the checklist should be mandatory for every case.</td><td>5</td><td>1</td><td>5</td><td>1</td><td>5</td><td>0</td></tr><tr><td>Support</td><td>Surgical personnel support the use of the checklist.</td><td>5</td><td>1</td><td>4</td><td>1</td><td>5</td><td>5</td></tr><tr><td> </td><td>Anaesthetic personnel support the use of the checklist.</td><td>4</td><td>2</td><td>4</td><td>1</td><td>5</td><td>4</td></tr><tr><td> </td><td>Nursing staff support the use of the checklist.</td><td>5</td><td>0</td><td>4</td><td>1</td><td>5</td><td>5</td></tr><tr><td> </td><td>Senior theatre personnel support the use of the checklist.</td><td>5</td><td>2</td><td>4</td><td>1</td><td>5</td><td>5</td></tr><tr><td> </td><td>Junior theatre personnel support the use of the checklist.</td><td>5</td><td>1</td><td>4</td><td>1</td><td>5</td><td>5</td></tr><tr><td> </td><td>Management support the use of the checklist.</td><td>5</td><td>2</td><td>5</td><td>1</td><td>5</td><td>5</td></tr><tr><td>Initiate</td><td>I have initiated the use of the checklist in the past.</td><td>5</td><td>2</td><td>1</td><td>3</td><td>5</td><td>0</td></tr><tr><td> </td><td>I intend to initiate the use of the checklist in the future.</td><td>5</td><td>1</td><td>3</td><td>1.75</td><td>5</td><td>0</td></tr><tr><td>Barriers</td><td>The requirement for signatures.</td><td>4</td><td>2.5</td><td>5</td><td>3</td><td>5</td><td>1</td></tr><tr><td> </td><td>Lack of assertiveness of staff.</td><td>4</td><td>2</td><td>4</td><td>2.5</td><td>4</td><td>1</td></tr><tr><td> </td><td>Lack of time.</td><td>4</td><td>2</td><td>4</td><td>2.75</td><td>4</td><td>1</td></tr><tr><td> </td><td>Lack of training.</td><td>4</td><td>2</td><td>4</td><td>2</td><td>4</td><td>1.5</td></tr><tr><td> </td><td>The lack of an electronic version of the checklist.</td><td>3</td><td>2</td><td>5</td><td>3</td><td>3</td><td>2</td></tr></table>
0c9938f7f74263c62bce1af30e6d0f00f5e0409ec886504208224db36dbeb752.png
complex
<table><tr><td>Research problem</td><td>Tool/Instrument</td><td>Authors</td></tr><tr><td rowspan="7">Nausea and vomiting</td><td>Nausea Vomiting Pregnancy QOL (NVP QOL)</td><td>[8] Canada</td></tr><tr><td>Pregnancy Unique Questionnaire Emesis (PUQE)</td><td>[9] Canada, [10] Canada</td></tr><tr><td>McGill nausea questionnaire</td><td>[11] Canada</td></tr><tr><td>Rhodes&#8217; scores (RI)</td><td>[12] Canada</td></tr><tr><td>Short form &#8211; 36 (SF-36)</td><td>[13] China</td></tr><tr><td>SF-12, NVP specific QOL</td><td>[14] Canada</td></tr><tr><td>NVPQOL, SF-36, SCL90</td><td>[15] USA</td></tr><tr><td rowspan="2">Irritable bladder</td><td>Incontinence Impact Questionnaire (IIQ), Urogenital Distress Inventory (UDI)</td><td>[6] Netherlands</td></tr><tr><td>Incontinence Questionnaire Short Form (ICIQ-SF)</td><td>[16] Turkey</td></tr><tr><td rowspan="3">Back pains</td><td>Nottingham Health Profile (NHP) Disability Rating Index (DRI)</td><td>[17] Sweden</td></tr><tr><td>Pregnancy Mobility Index (PMI)</td><td>[18] Netherlands</td></tr><tr><td>WHOQOL-BREF</td><td>[19] Turkey</td></tr><tr><td rowspan="4">Anxiety and depression</td><td>Finnish modification of SF of the beck depression inventory and anxiety</td><td>[20] Finland</td></tr><tr><td>Hospital Anxiety and Depression Scale (HADS)</td><td>[21] Sweden</td></tr><tr><td>EPDS, SF-36v2</td><td>[22] China</td></tr><tr><td>WHOQOL-BREF, EPDS</td><td>[23] Austria</td></tr></table>
501c4ba6ff516a18de4c327ba2338caf07a7fc8daa8e5fa41992026f39465f67.png
complex
<table><tr><td>Laboratory site</td><td>Samples (<i>n</i>)</td><td colspan="2">Number of devices (<i>n</i>)</td><td colspan="2">Runs per day (<i>n</i>)</td><td>Approximately overall time requirement</td></tr><tr><td></td><td></td><td>Sprinter XL</td><td>EUROPattern</td><td>Screening</td><td>Titer</td><td></td></tr><tr><td>Houston, TX, USA</td><td>141</td><td>1</td><td>1</td><td>1</td><td>1</td><td>06:00 h</td></tr><tr><td>Tampa, FL, USA</td><td>134</td><td>1</td><td>1</td><td>1</td><td>1</td><td>06:10 h</td></tr><tr><td>Dallas, TX, USA</td><td>187</td><td>1</td><td>1</td><td>1</td><td>1</td><td>06:40 h</td></tr><tr><td>Phoenix, AZ, USA</td><td>231</td><td>1</td><td>1</td><td>1</td><td>1</td><td>07:10 h</td></tr><tr><td>Birmingham, AL, USA</td><td>236</td><td>2</td><td>2</td><td>2</td><td>1</td><td>06:30 h</td></tr><tr><td>Burlington, NC, USA</td><td>471</td><td>2</td><td>2</td><td>2</td><td>2</td><td>07:10 h</td></tr><tr><td>Dublin, OH, USA</td><td>330</td><td>2</td><td>2</td><td>2</td><td>2</td><td>07:10 h</td></tr><tr><td>Raritan, NJ, USA</td><td>568</td><td>3</td><td>3</td><td>3</td><td>3</td><td>07:05 h</td></tr></table>
2df8860ee557bb7692b3e3b47b3b47cf7cf173b76f0c9b0870dea45d819ddfcf.png
complex
<table><tr><td>School</td><td>Arm allocation<sup>a</sup></td><td>Number of girls in school</td><td>Provided consent (n, %)</td><td>Enrolled in intervention (n, %)</td><td colspan="2">Provided baseline data (n, %)</td><td>Mean weekly attendance during intervention (n, %)</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Questionnaire</td><td>Accelerometer<sup>b</sup></td><td> </td></tr><tr><td>1</td><td>A</td><td>106</td><td>43 (40.6)</td><td>30 (28.3)</td><td>30 (100)</td><td>28 (93.3)</td><td>15.4 (51.3)</td></tr><tr><td>2</td><td>A</td><td>100</td><td>43 (43.0)</td><td>30 (30.0)</td><td>30 (100)</td><td>29 (96.7)</td><td>24.8 (82.6)</td></tr><tr><td>3</td><td>A</td><td>112</td><td>42 (37.5)</td><td>30 (26.8)</td><td>30 (100)</td><td>30 (100)</td><td>25.9 (86.3)</td></tr><tr><td>4</td><td>B</td><td>112</td><td>57 (50.9)</td><td>-</td><td>30 (100)</td><td>30 (100)</td><td>-</td></tr><tr><td>5</td><td>C</td><td>83</td><td>44 (53.0)</td><td>-</td><td>30 (100)</td><td>29 (96.7)</td><td>-</td></tr><tr><td>6</td><td>C</td><td>101</td><td>41 (40.6)</td><td>-</td><td>30 (100)</td><td>27 (90)</td><td>-</td></tr><tr><td>7</td><td>B</td><td>179</td><td>48 (26.8)</td><td>-</td><td>30 (100)</td><td>30 (100)</td><td>-</td></tr></table>
275e914a5e868f3acf45ecd7408bc238e77330c09d39c9c8a77a88782fce87e7.png
simple
<table><tr><td>Characteristic</td><td>&#946;</td><td>Standard error</td><td><i>P</i></td></tr><tr><td>Baseline</td><td>-5.169</td><td>1.388</td><td>0.000</td></tr><tr><td>Proband breast cancer diagnosis &#8804;35 years</td><td>2.791</td><td>1.379</td><td>0.043</td></tr><tr><td>Proband breast cancer diagnosis 36-39 years</td><td>2.248</td><td>1.365</td><td>0.100</td></tr><tr><td>Proband breast cancer diagnosis 40-49 years</td><td>1.763</td><td>1.355</td><td>0.193</td></tr><tr><td>Proband breast cancer diagnosis 50-59 years</td><td>1.065</td><td>1.354</td><td>0.431</td></tr><tr><td>Proband bilateral breast cancer at any age</td><td>1.036</td><td>0.462</td><td>0.025</td></tr><tr><td>Proband ovarian cancer at any age</td><td>0.238</td><td>1.469</td><td>0.871</td></tr><tr><td>Proband triple-negative breast cancer at any age</td><td>1.323</td><td>0.331</td><td>0.000</td></tr><tr><td>For each relative with cancer:</td><td></td><td></td><td></td></tr><tr><td> First degree, breast cancer diagnosis &#8804;39 years</td><td>0.950</td><td>0.369</td><td>0.010</td></tr><tr><td> First degree, breast cancer diagnosis 40-49 years</td><td>1.450</td><td>0.386</td><td>0.000</td></tr><tr><td> First degree, breast cancer diagnosis 50-59 years</td><td>1.445</td><td>0.450</td><td>0.001</td></tr><tr><td> First degree, breast cancer diagnosis 60+ years</td><td>0.207</td><td>0.646</td><td>0.749</td></tr><tr><td> First degree, ovarian cancer at any age</td><td>2.556</td><td>0.769</td><td>0.001</td></tr><tr><td> Second degree, breast cancer diagnosis at any age</td><td>0.359</td><td>0.272</td><td>0.187</td></tr><tr><td> Second degree, ovarian cancer diagnosis at any age</td><td>1.861</td><td>0.832</td><td>0.025</td></tr></table>
aff44afa7135e82abc33f11de7e5dbe6b226abfc14eba6837374a8e344fb5f1c.png
complex
<table><tr><td> </td><td>Normal thyroid (n.4)</td><td>Hyperplasia/Benign nodules (n.5)</td><td>Thyroid carcinoma (n.7)</td></tr><tr><td>Video intensity UCA<sub>IGg</sub></td><td colspan="3"> </td></tr><tr><td>Video intensity difference</td><td>11.3 (9.4-14.7)</td><td>12.2 (8.5-19.6)</td><td>19.4 (11.4-22.6)</td></tr><tr><td>Video intensity UCA<sub>VEGFR2</sub></td><td colspan="3"> </td></tr><tr><td>Video intensity difference</td><td>10.9 (10.3-14.9)</td><td>13.3 (10.8-15.8)</td><td>30.1 (25.1-35.6)* &#167;</td></tr></table>
73525cea8b520738639021190ff42bc38f0aa5872e22bfafdf96a97ba09bb878.png
simple
<table><tr><td></td><td>Mechanism of action</td><td>Drugs</td><td>Trial (reference)</td><td>Study population</td><td>Benefits</td><td>Common severetoxicities</td></tr><tr><td>Apoptosis</td><td>PARP inhibitors</td><td>Olaparib</td><td>Phase II (127)</td><td>Recurrent/metastatic adult ES (failure to prior CH), <i>n</i> = 12 patients</td><td>NO responses SD: 4 patients, TTP: 5.7 weeks</td><td>No significant toxicities</td></tr><tr><td></td><td>Heat shock protein inhibitors</td><td>Retaspimycin (Hsp-90 INH)</td><td>Phase I (128)</td><td>Metastatic and/or unresectable STS, <i>n</i> = 54 patients</td><td>PR: 2 patients (proof of clinical activity)</td><td>Grade 3&#8211;4:Fatigue Nausea and vomiting Headache Artharalgia</td></tr><tr><td></td><td>Proteaseome inhibitor</td><td>Bortezomib</td><td>Phase II (129)</td><td>Metastatic OS, ES, RMS, and STS with no prior treatment for advanced disease, <i>n</i> = 25 patients</td><td>Lack of benefit (trial prematurely closed)</td><td>Grade 3&#8211;4:Neuropathy Asthenia Myalgias</td></tr><tr><td></td><td>MDM2 inhibitor</td><td>RG7112</td><td>Proof of mechanism study (130)</td><td>WDLS or DDLS with MDM2 amplification receive RG7112 prior to surgery, <i>n</i> = 20 patients</td><td>SD: 14 patients, IHQ: activation of p53 pathway</td><td>Grade 3&#8211;4Neutropenia Thrombocytopenia</td></tr><tr><td></td><td></td><td></td><td>Phase I (131)</td><td>Phase I trial with extension cohort for sarcoma patients, <i>n</i> = 30 (sarcoma patients)</td><td>Metabolic responses (PET-CT) IHQ: activation of p53 (MDM2-independent)</td><td>Grade 3&#8211;4 Cytopenias</td></tr><tr><td></td><td>PI3K-AKT-mTOR pathway inhibitors</td><td>Ridaforolimus (mTOR INH)</td><td>Phase II (132)</td><td>Pre-treated advanced bone and STS, <i>n</i> = 212 patients</td><td>RR: 1.9%, clinical benefit: 28.8%</td><td>Grade 3&#8211;4Fatigue Stomatitis Hypertriglyceridemia Anemia Thrombocytopenia</td></tr><tr><td></td><td></td><td></td><td>Phase III (133)</td><td>Advanced bone and STS with clinical benefit to previous CH were randomized to maintenance Ridaforolimus or Placebo, <i>n</i> = 711 patients</td><td>Improvement in PFS (17.7 weeks with Ridaforolimus vs. 14.6 weeks with Placebo, HR: 0.72, <i>p</i>: 0.001)</td><td>Similar to previous study</td></tr><tr><td></td><td></td><td>Everolimus (mTOR INH)</td><td>Phase II (134)</td><td>Pre-treated advanced bone and STS, <i>n</i> = 41 patients</td><td>Poor clinical activity</td><td>Grade 3&#8211;4Hyperglicemia Stomatitis Pain Asthenia</td></tr><tr><td></td><td>Anti-angiogenic therapy</td><td>Sorafenib (VEGFR2, VEGFR3, PDGFR, and c-Kit INH)</td><td>Phase II (135)</td><td>Pre-treated advanced STS, <i>n</i> = 101 patients</td><td>RR: 14.5%, SD: 32.9% (leiomyosarcoma better PFS)</td><td>Grade 3&#8211;4Fatigue Diarrhea Hand&#8211;foot Syndrome Nausea and vomiting</td></tr><tr><td></td><td></td><td>Pazopanib (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and c-Kit INH)</td><td>Phase III (136)</td><td>Pre-treated non-adipocytic STS randomized to PAZOPANIB vs. PLACEBO, <i>n</i> = 369 patients</td><td>Improvement in PFS (4.6 months with PAZOPANIB vs. 1.6 months with Placebo, HR: 0.31, <i>p</i> &lt; 0.0001)</td><td>Grade 3&#8211;4Asthenia Hypertension Anorexia Alteration of transaminases</td></tr><tr><td>Mitotic catastrophe</td><td>CDK inhibitors</td><td>Palbociclib (CDK4 and CDK6 INH)</td><td>Phase II (137)</td><td>WDLS or DDLS with CDK4 amplification and pRb expression</td><td>66% of patients free of PD at 12 weeks</td><td>Grade 3&#8211;4Anemia Neutropenia Thrombocytopenia</td></tr></table>
d631f34543f7c4b4b4cf73eec2fe3723fb6ab147f16758cf65ea4153d3f52887.png
complex
<table><tr><td rowspan="2">Sample</td><td rowspan="2"><i>L</i> / cov</td><td colspan="6">Compression rates</td></tr><tr><td>Assembltrie</td><td>Assembltrie (corrected)</td><td>Orcom</td><td>BEETL</td><td>Mince</td><td>k-Path</td></tr><tr><td>SRR554369</td><td>100/25</td><td>0.369</td><td>0.345</td><td>0.518</td><td>1.133</td><td>0.484</td><td>0.673</td></tr><tr><td>SRR327342</td><td>63/80</td><td>0.272</td><td>0.291</td><td>0.304</td><td>0.986</td><td>0.312</td><td>0.384</td></tr><tr><td>MH0001.081026</td><td>44/NA</td><td>0.781</td><td>0.758</td><td>0.804</td><td>1.785</td><td>0.786</td><td>2.545</td></tr><tr><td>SRR870667</td><td>108/20</td><td>1.821</td><td>1.733</td><td>0.884</td><td>1.287</td><td>0.735</td><td>0.707</td></tr><tr><td>ERR174310</td><td>101/7</td><td>0.701</td><td>0.570</td><td>0.686</td><td>1.493</td><td>0.746</td><td>0.797</td></tr><tr><td>ERP001775</td><td>101/20</td><td>0.350</td><td>0.322</td><td>0.364</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Sim. <i>T. cacao</i></td><td>108/19</td><td>0.538</td><td>0.479</td><td>0.667</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>NA12878</td><td>101/7</td><td>0.444</td><td>N/A</td><td>0.650</td><td>N/A</td><td>N/A</td><td>N/A</td></tr></table>
96cfe37fab46c4089201e16ffa83510b442f886e6c077ae1921769808f1dfa02.png
simple
<table><tr><td>Library</td><td>total reads</td><td>reads length(bp)</td><td>Total mapped</td><td>mapped%</td><td>mapped pairs</td><td>mapped paired%</td><td>Mapped genes<sup>*</sup></td></tr><tr><td>T1</td><td>23,708,937</td><td>101</td><td>33,274,003</td><td>70.17%</td><td>15,623,535</td><td>65.90%</td><td>15,594</td></tr><tr><td>N1</td><td>16,433,264</td><td>101</td><td>18,224,025</td><td>55.45%</td><td>8,108,072</td><td>49.34%</td><td>16,245</td></tr><tr><td>T2</td><td>46,059,548</td><td>101</td><td>38,593,916</td><td>83.79%</td><td>18,494,595</td><td>80.31%</td><td>17,549</td></tr><tr><td>N2</td><td>40,830,844</td><td>101</td><td>34,288,810</td><td>83.98%</td><td>16,370,875</td><td>80.19%</td><td>17,584</td></tr></table>
8cc4e07a12aac024065b66bb7d695266dd8c8949bf50d43fd351347e8da6068f.png
complex
<table><tr><td></td><td colspan="2">Flg22-responsive genes*</td><td colspan="2">Light-responsive genes**</td><td>Overlap genes</td><td><i>P</i>-value<sup>***</sup></td></tr><tr><td>Flg22-induced light-dependent genes</td><td>3579</td><td>(flg22-up)</td><td>2576</td><td>(light-dependent)</td><td>536</td><td>8.790e-24</td></tr><tr><td>Flg22-induced light-repressed genes</td><td>3579</td><td>(flg22-up)</td><td>2161</td><td>(light-repressed)</td><td>239</td><td>1.084e-05</td></tr><tr><td>Flg22-repressed light-dependent genes</td><td>4159</td><td>(flg22-down)</td><td>2576</td><td>(light-dependent)</td><td>359</td><td>2.599e-04</td></tr><tr><td>Flg22-repressed light-repressed genes</td><td>4159</td><td>(flg22-down)</td><td>2161</td><td>(light-repressed)</td><td>370</td><td>0.15</td></tr></table>
f5e150fa393074bf230e007a1757f82f79e563f1ac9a687c7a3ad2959ac3b20c.png
complex
<table><tr><td rowspan="2">Patient No.</td><td rowspan="2">Ethnicity</td><td colspan="5">Biochemical findings</td><td rowspan="2">Phenotype</td><td rowspan="2"><i>ACADS</i> genotype</td></tr><tr><td>C4<sup>a</sup></td><td>C4/C2<sup>a</sup></td><td>C4/C3<sup>a</sup></td><td>C4/C8<sup>a</sup></td><td>EMA<sup>b</sup></td></tr><tr><td>1</td><td>R</td><td>1.53</td><td>0.21</td><td>1.35</td><td>40.38</td><td>N/A</td><td>microcephaly, DD/ID, marked hypotonus, horizontal nystagmus</td><td rowspan="9">c.310_312delGAG/c.310_312delGAG</td></tr><tr><td>9</td><td>R</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>634</td><td>DD/ID, apnoic pause, bleeding into the adrenal glands in the neonatal age, hypoglycaemia</td></tr><tr><td>10</td><td>R</td><td>1.44</td><td>0.05</td><td>0.81</td><td>30.64</td><td>363</td><td>central hypotonus with acral hypertonus, laryngomalatia</td></tr><tr><td>12</td><td>R</td><td>1.07</td><td>0.07</td><td>1.07</td><td>40.75</td><td>146</td><td>epilepsy, hypotonus, irritability, cerebral palsy, pectus carinatum, kyphoscoliosis</td></tr><tr><td>14</td><td>R</td><td>0.97</td><td>0.08</td><td>0.61</td><td>59.6</td><td>1070</td><td>recurrent sepsis, MAC, hepatosplenomegaly, severe hepatopathy along with gastroenteritis</td></tr><tr><td>15</td><td>C</td><td>2.77</td><td>0.11</td><td>3.26</td><td>60.23</td><td>169</td><td>mild MAC in neonatal age, at age 2 yo - DD/ID, hypotonus, at age 3 yo &#8211; without DD/ID</td></tr><tr><td>17</td><td>R</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>329</td><td>severe DD/ID, parents consanguinity, MAC, brother &#8211; DD/ID with no biochemical positivity to SCADD</td></tr><tr><td>23</td><td>R</td><td>1.19</td><td>0.07</td><td>0.57</td><td>129</td><td>322</td><td>hypoglycaemia, elevated CK</td></tr><tr><td>24</td><td>R</td><td>1.00</td><td>0.10</td><td>0.53</td><td>60.88</td><td>N/A</td><td>mild MAC</td></tr><tr><td>25</td><td>R</td><td>1.90</td><td>0.14</td><td>1.98</td><td>52.34</td><td>657</td><td>DD</td><td rowspan="4">c.310_312delGAG/c.1138C&gt;T</td></tr><tr><td>32</td><td>R</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>306</td><td>prematurity, severe DD/ID, quadruparesis, recurrent hypoglycaemia</td></tr><tr><td>33</td><td>R</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>965</td><td>DD/ID(milder than brother - patient No. 32)</td></tr><tr><td>35</td><td>R</td><td>1.52</td><td>0.08</td><td>0.94</td><td>77.08</td><td>433</td><td>mild hepatomegaly, hyperammonemia, MAC</td></tr><tr><td>52</td><td>N/A</td><td>0.61</td><td>0.06</td><td>5.28</td><td>10.18</td><td>N/A</td><td>DD/ID <sup>c</sup></td><td rowspan="5">c.310_312delGAG/c.625G&gt;A</td></tr><tr><td>53</td><td>R</td><td>1.20</td><td>0.07</td><td>0.72</td><td>17.93</td><td>135</td><td>short stature, ophtalmoplegia (first sign &#8211; suspicion for congenital myasthenia), hypomimic facies, severe kyphoscoliosis, DD/ID, cachexia, hypotonus, respiratory failure, diffuse brain edema, coma vigile (high suspicion for other unknown neuromuscular disease)</td></tr><tr><td>54</td><td>R</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>71</td><td>epilepsy</td></tr><tr><td>55</td><td>R</td><td>0.44</td><td>0.03</td><td>0.19</td><td>50.42</td><td>54</td><td>recidivating granulomatous hepatopathy with hepatomegaly, mild hypertonus, mild DD/ID, epilepsy, apnoic pauses</td></tr><tr><td>56</td><td>R</td><td>0.86</td><td>0.03</td><td>0.41</td><td>21.15</td><td>110</td><td>recurrent seizures</td></tr></table>
262b03b0c3ed1c1e083dfdac666c8e1661a058726f2a5970970f521a1a3c0177.png
complex
<table><tr><td rowspan="2"></td><td></td><td>Non-surgical <i>n</i> = 261</td><td>Bariatric surgery <i>n</i> = 301</td><td>Adjusted for gender/age/BMI</td><td></td><td></td></tr><tr><td>Range</td><td>Mean (SD)</td><td>Mean (SD)</td><td>F</td><td><i>P</i></td><td>&#951;p<sup>2</sup></td></tr><tr><td colspan="7">Family obesity</td></tr><tr><td> - parent/sibling + as a child</td><td>0&#8211;2</td><td>1.0 (0.7)</td><td>1.3 (0.7)</td><td>8.98</td><td>&lt;0.01</td><td>0.017</td></tr><tr><td> - partner + own children</td><td>0&#8211;2</td><td>0.7 (0.7)</td><td>0.7 (0.6)</td><td>0.01</td><td>0.93</td><td></td></tr><tr><td colspan="7">Current behavior</td></tr><tr><td colspan="7"> Unhealthy eating habits</td></tr><tr><td>- Total</td><td>1&#8211;5</td><td>2.4 (0.7)</td><td>2.5 (0.7)</td><td>0.73</td><td>0.39</td><td></td></tr><tr><td>- Snacking between meals</td><td>1&#8211;5</td><td>3.0 (0.9)</td><td>3.1 (1.0)</td><td>0.82</td><td>0.37</td><td></td></tr><tr><td>- Snacking on sweets</td><td>1&#8211;5</td><td>2.8 (1.0)</td><td>2.8 (1.0)</td><td>1.13</td><td>0.29</td><td></td></tr><tr><td>- Drinking soda drinks</td><td>1&#8211;5</td><td>2.6 (1.4)</td><td>3.0 (1.4)</td><td>6.71</td><td>&lt;0.01</td><td>0.012</td></tr><tr><td>- Night time eating</td><td>1&#8211;5</td><td>1.3 (0.7)</td><td>1.2 (0.6)</td><td>3.57</td><td>0.11</td><td></td></tr><tr><td> Physical activity MET-minutes/week</td><td>0&#8211;14,958</td><td>2292.5 (2445.3)</td><td>1844.2 (2290.6)</td><td>3.96</td><td>&lt;0.05</td><td>0.008</td></tr><tr><td> Alcohol use</td><td>1&#8211;9</td><td>4.5 (1.8)</td><td>4.0 (1.7)</td><td>2.12</td><td>0.14</td><td></td></tr><tr><td> Self-monitoring of weight</td><td>1&#8211;7</td><td>3.1 (1.5)</td><td>2.7 (1.5)</td><td>3.70</td><td>0.06</td><td></td></tr><tr><td colspan="7">Dieting history</td></tr><tr><td> % yrs. Dieting</td><td>0&#8211;88</td><td>47.6 (20.1)</td><td>53.9 (17.4)</td><td>11.93</td><td>&lt;0.001</td><td>0.023</td></tr><tr><td> # organized diet programs</td><td>0&#8211;25</td><td>2.7 (2.9)</td><td>3.6 (4.1)</td><td>7.31</td><td>&lt;0.01</td><td>0.014</td></tr><tr><td> # 3 day diets past year</td><td>0&#8211;25</td><td>2.5 (4.2)</td><td>3.2 (4.6)</td><td>1.07</td><td>0.30</td><td></td></tr><tr><td> # lost &gt;10 kg</td><td>0&#8211;12</td><td>3.1 (2.8)</td><td>4.2 (3.4)</td><td>8.36</td><td>&lt;0.01</td><td>0.017</td></tr><tr><td colspan="7"> Diet strategies</td></tr><tr><td>-Total</td><td>0&#8211;11</td><td>4.0 (2.3)</td><td>4.9 (2.3)</td><td>13.75</td><td>&lt;0.001</td><td>0.025</td></tr><tr><td>- Less fat/carbs/sweets</td><td>0&#8211;3</td><td>1.6 (1.1)</td><td>1.8 (1.0)</td><td>1.28</td><td>0.26</td><td></td></tr><tr><td>- Skipping meals/eat less/fasted</td><td>0&#8211;3</td><td>1.3 (0.9)</td><td>1.5 (0.9)</td><td>6.89</td><td>&lt;0.01</td><td>0.013</td></tr><tr><td>- Use laxatives/ vomiting/diet drugs/diuretic drugs</td><td>0&#8211;4</td><td>0.6 (0.8)</td><td>1.0 (0.9)</td><td>16.75</td><td>&lt;0.001</td><td>0.030</td></tr></table>
dc1a788177e60ac47724168b1fcec85bab74be3bb50fdbb303f5eedb5fb8b195.png
simple
<table><tr><td>GeneID</td><td>Gene Description</td><td>miRNAs</td><td>miRDB (target score)</td><td>TargetScan (Context + Percentile)</td></tr><tr><td>ABHD3</td><td>Abhydrolase domain containing 3</td><td>miR-1244, miR-130a, miR-205</td><td>74, &gt; 85</td><td>84</td></tr><tr><td>CCNJ</td><td>Cyclin J</td><td>miR-205-5p</td><td>90</td><td>98</td></tr><tr><td>CHAMP1/ZNF828</td><td>Chromosome alignment maintaining phosphoprotein 1</td><td>miR-7-5p, miR-378a-3p</td><td>60-96</td><td>96</td></tr><tr><td>MYB</td><td>v-Myb myeloblastosis viral oncogene homolog (avian)</td><td>miR-15b-5p, miR-16-5p</td><td>74</td><td>96</td></tr><tr><td>PIK3CD</td><td>Phosphoinositide-3-kinase, catalytic, delta polypeptide</td><td>miR-7-5p</td><td>94</td><td>91</td></tr><tr><td>VEGFA</td><td>Vascular endothelial growth factor A</td><td>miR-205, miR-15b</td><td>79</td><td>97</td></tr><tr><td>FGD4</td><td>RhoGEF and PH domain containing 4</td><td>miR-17, miR-106a, miR-20a</td><td>100</td><td>98</td></tr><tr><td>SPOPL</td><td>Speckle-type POZ protein-like</td><td>miR-9-3p</td><td>97</td><td>97</td></tr><tr><td>RAB9B</td><td>RAB9B, member RAS oncogene family</td><td>miR-15b-5p, miR-16-5p, miR-130a-3P, miR-9-5p</td><td>67-86</td><td>67-86</td></tr><tr><td>EGFR</td><td>Epidermal growth factor receptor</td><td>miR-7</td><td>81</td><td>93</td></tr><tr><td>E2F1</td><td>E2F transcription factor 1</td><td>miR-205, miR-17, miR-20b</td><td>77</td><td>80</td></tr><tr><td>DOK4/IRS-5</td><td>Docking protein 4</td><td>miR-205</td><td>N/A</td><td>94</td></tr></table>
9a62fc7fa57489bc7287ff6cc3263d74a083c7b636fb1c3968d83702520b4643.png
simple
<table><tr><td>Diagnosis</td><td><i>n</i></td></tr><tr><td>Breast cancer</td><td>200</td></tr><tr><td>Glioma</td><td>144</td></tr><tr><td>Cervical carcinoma</td><td>117</td></tr><tr><td>Meningioma</td><td>72</td></tr><tr><td>Pituary adenoma</td><td>50</td></tr><tr><td>Cerebral lymphoma</td><td>49</td></tr></table>
94750d3460c6ee2c4b6ef305bad409c0ccca224b91f8defcbfe8ffe43ff4047a.png
complex
<table><tr><td rowspan="3"></td><td colspan="4">Prague</td><td colspan="4">4 cities</td></tr><tr><td colspan="2">CAPI</td><td colspan="2">CAWI</td><td colspan="2">CAPI</td><td colspan="2">CAWI</td></tr><tr><td><i>coeff.</i></td><td><i>s.e.</i></td><td><i>coeff.</i></td><td><i>s.e.</i></td><td><i>coeff.</i></td><td><i>s.e.</i></td><td><i>coeff.</i></td><td><i>s.e.</i></td></tr><tr><td><i>&#945;</i></td><td>2.26</td><td>0.312</td><td>1.25</td><td>0.268</td><td>0.97</td><td>0.217</td><td>0.70</td><td>0.222</td></tr><tr><td><i>&#946;</i></td><td>&#8722;0.00056</td><td>4.95E-05</td><td>&#8722;0.00033</td><td>3.99E-05</td><td>&#8722;0.00054</td><td>3.68E-05</td><td>&#8722;0.00051</td><td>3.64E-05</td></tr><tr><td><i>&#948;</i></td><td>0.095</td><td>0.0158</td><td>0.123</td><td>0.0312</td><td>0.083</td><td>0.0232</td><td>0.055</td><td>0.0256</td></tr><tr><td>N of obs.</td><td>1,365</td><td></td><td>1,840</td><td></td><td>2,585</td><td></td><td>2,635</td><td></td></tr><tr><td>VSL (mill Euro)</td><td>4.02</td><td></td><td>3.85</td><td></td><td>1.79</td><td></td><td>1.37</td><td></td></tr></table>
68bf6013a27a94ee070d99fa6b144f7c5e569b33358471e1936ecbc991b1db58.png
simple
<table><tr><td></td><td>Food resource referrals - 2016</td></tr><tr><td>Pediatrics clinic</td><td>438</td></tr><tr><td>Internal medicine clinic</td><td>140</td></tr><tr><td>Family medicine clinic</td><td>246</td></tr><tr><td>Emergency department</td><td>55 (25 Attending Physicians, 22 Resident Physicians, 8 Physician Assistants)</td></tr><tr><td>Psychiatry clinic</td><td>52</td></tr></table>
274ba4ecec724c731e0d45ef5acd0bb4f01f06f65870af25b7925d61351f5421.png
simple
<table><tr><td>Reference</td><td>Sample number</td><td>Histotype</td><td>Results</td></tr><tr><td>Sawabata et al. (17)</td><td>9</td><td>NSCLC</td><td>CTC-positive in 4/9 patients. No recurrence after surgery</td></tr><tr><td>Bevilacqua et al. (19)</td><td>5</td><td>SCLC</td><td>CTC have a role in SCLC patients diagnosis</td></tr><tr><td>Tanaka et al. (20)</td><td>150</td><td>NSCLC and SCLC</td><td>CTC well differentiate stage I from stage IV tumors</td></tr><tr><td>Hou et al. (21)</td><td>50</td><td>SCLC</td><td>CTCs &#8805; 2 in 86%. Higher CTC number &#8594; shorter OS. CTC-positive decreased after CT (60%)</td></tr><tr><td>Naito et al. (22)</td><td>51</td><td>SCLC</td><td>CTCs detected in 68.6, 26.5, and 67.6% at B, post-CT, and R, respectively. CTCs &gt; 8 &#8594; worse OS</td></tr><tr><td>Hiltermann et al. (23)</td><td>59</td><td>SCLC</td><td>Median CTCs at B = 6 and 63 in localized and metastatic disease, respectively. CTCs decrease after CT &#8594; strong predictor of OS</td></tr><tr><td>Normanno et al. (24)</td><td>60</td><td>SCLC</td><td>CTCs identified in 90% at B and associated to involved organs. CTC reduction higher than 89% after CT &#8594; better OS</td></tr><tr><td>Hou et al. (25)</td><td>97</td><td>SCLC</td><td>CTCs present in 85%. CTCs &#8805; 50 at B &#8594; worse OS. Failure of CTC to decrease &lt;50 after CT &#8594; worse prognosis</td></tr><tr><td>Krebs et al. (26)</td><td>101</td><td>NSCLC</td><td>CTC number at B higher in stage IV than stage III (60 and 27, respectively).CTCs number &#8594; prognostic factor for PFS and predictor of OS after first cycle of CT</td></tr><tr><td>Hirose et al. (27)</td><td>33</td><td>NSCLC</td><td>CTCs positive in 36.4 and 15.2% had five or more CTCs before CT. Positive CTCs patients &#8594; progressive disease</td></tr><tr><td>Punoose et al. (28)</td><td>41</td><td>NSCLC</td><td>CTCs identified in 78% at B. CTC decrease during CT &#8594; longer PFS</td></tr><tr><td>Muinelo-Romay et al. (29)</td><td>43</td><td>NSCLC</td><td>CTCs detected in 41.9%. CTCs &#8805; 5 &#8594; shorter PFS and OS. CTC decrease after second cycle of CT &#8594; higher response and better PFS and OS</td></tr><tr><td>Isobe et al. (30)</td><td>24</td><td>NSCLC</td><td>CTCs detected in 33.3%. <i>EGFR</i> mutations in cfDNA: 25%. EGFR mutation rate in cfDNA higher when CTCs &#8805; 2</td></tr><tr><td>Swennenhuis et al. (31)</td><td>10</td><td>NSCLC and SCLC</td><td>DNA isolation and sequencing from a single CTC</td></tr></table>
3acd767fddfdac5cc2a92be4f9fb8bddd8c876ca3ecce8164966a887762ff948.png
complex
<table><tr><td rowspan="2"></td><td rowspan="2"><i>B</i></td><td rowspan="2"><i>S.E.</i></td><td rowspan="2"><i>Wald</i></td><td rowspan="2"><i>p</i></td><td rowspan="2"><i>OR</i></td><td colspan="2">95% CI</td></tr><tr><td>Min</td><td>Max</td></tr><tr><td>Predisposing characteristics</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Single-parent family</td><td>1.142</td><td>0.403</td><td>8.040</td><td>0.005</td><td>3.132</td><td>1.423</td><td>6.894</td></tr><tr><td>Not seeking health information actively</td><td>0.620</td><td>0.223</td><td>7.724</td><td>0.005</td><td>1.860</td><td>1.201</td><td>2.880</td></tr><tr><td>Enabling characteristics</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Financial status (Able to meet basic needs as reference)</td><td></td><td></td><td>7.776</td><td>0.020</td><td></td><td></td><td></td></tr><tr><td>Just to meet basic needs</td><td>0.422</td><td>0.263</td><td>2.570</td><td>0.109</td><td>1.524</td><td>0.912</td><td>2.553</td></tr><tr><td>Cannot meet basic needs</td><td>0.959</td><td>0.344</td><td>7.760</td><td>0.005</td><td>2.610</td><td>1.329</td><td>5.125</td></tr><tr><td>Need</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Perceived health status (Excellent as reference)</td><td></td><td></td><td>8.473</td><td>0.037</td><td></td><td></td><td></td></tr><tr><td>Good</td><td>0.114</td><td>0.273</td><td>0.176</td><td>0.675</td><td>1.121</td><td>0.657</td><td>1.914</td></tr><tr><td>Fair</td><td>0.606</td><td>0.305</td><td>3.930</td><td>0.047</td><td>1.832</td><td>1.007</td><td>3.334</td></tr><tr><td>Poor</td><td>1.827</td><td>0.868</td><td>4.431</td><td>0.035</td><td>6.217</td><td>1.134</td><td>34.075</td></tr><tr><td>Constant</td><td>&#8722;1.479</td><td>0.299</td><td>24.413</td><td>0.001</td><td>0.228</td><td></td><td></td></tr></table>
6583eff8b804f10ce468e6c57a80cf9bcfd3c3ed3fa93e0f07f14a029e7ae122.png
simple
<table><tr><td> </td><td>ASRV</td><td>DGRV</td><td>ACRV</td><td>IIRV</td><td>PVRV</td><td>FV3</td><td>SSTIV</td><td>CH8/96</td><td>ESV/ECV</td><td>RTV</td><td>TRV</td></tr><tr><td>ASRV</td><td> </td><td>98.0</td><td>99.6</td><td>96.4</td><td>98.0</td><td>99.6</td><td>99.4</td><td>98.2</td><td>96.4</td><td>98.2</td><td>98</td></tr><tr><td>DGRV</td><td>98.8</td><td> </td><td>98.4</td><td>96.0</td><td>97.6</td><td>98.4</td><td>98.6</td><td>97.8</td><td>96</td><td>99.0</td><td>97.6</td></tr><tr><td>ACRV</td><td>100</td><td>98.8</td><td> </td><td>96.8</td><td>98.4</td><td>100</td><td>99.8</td><td>98.6</td><td>96.8</td><td>98.6</td><td>98.4</td></tr><tr><td>IIRV</td><td>95.8</td><td>96.4</td><td>95.8</td><td> </td><td>96.8</td><td>96.8</td><td>97.0</td><td>98.2</td><td>100</td><td>96.2</td><td>96.8</td></tr><tr><td>PVRV</td><td>98.2</td><td>98.2</td><td>98.2</td><td>95.2</td><td> </td><td>98.4</td><td>98.6</td><td>97.8</td><td>96.8</td><td>97.8</td><td>100</td></tr><tr><td>FV3</td><td>100</td><td>98.8</td><td>100</td><td>95.8</td><td>98.2</td><td> </td><td>99.8</td><td>98.6</td><td>96.8</td><td>98.6</td><td>98.4</td></tr><tr><td>SSTIV</td><td>99.4</td><td>99.4</td><td>99.4</td><td>96.4</td><td>98.8</td><td>99.4</td><td> </td><td>98.8</td><td>97.0</td><td>98.8</td><td>98.6</td></tr><tr><td>CH8/96</td><td>97.6</td><td>97.6</td><td>97.6</td><td>98.2</td><td>97.0</td><td>97.6</td><td>98.2</td><td> </td><td>98.2</td><td>98. 0</td><td>97.8</td></tr><tr><td>ESV/ECV</td><td>95.8</td><td>96.4</td><td>95.8</td><td>100</td><td>95.2</td><td>95.8</td><td>96.4</td><td>98.2</td><td> </td><td>96.2</td><td>96.8</td></tr><tr><td>RTV</td><td>98.8</td><td>100</td><td>98.8</td><td>96.4</td><td>98.2</td><td>98.8</td><td>99.4</td><td>97.6</td><td>96.4</td><td> </td><td>97.8</td></tr><tr><td>TRV</td><td>98.2</td><td>98.2</td><td>98.2</td><td>95.2</td><td>100</td><td>98.2</td><td>98.8</td><td>97.0</td><td>95.2</td><td>98.2</td><td> </td></tr></table>
bc7ff0ddd72cf51d2146f72c9fa0826723dd4d4ab8d36245fb7c24cd7b706223.png
complex
<table><tr><td rowspan="2">Characteristic</td><td>Lifestyle</td><td>Preventive screening</td><td>Choosing treatments</td><td>Choosing specialists</td><td>Choosing medications</td><td>Diagnostic testing</td></tr><tr><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td></tr><tr><td colspan="7">Gender</td></tr><tr><td> Male</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr><tr><td> Female</td><td>1.21 [0.97, 1.53]</td><td>1.10 [0.90, 1.36]</td><td>1.44 [1.17, 1.78]</td><td>1.46 [1.19, 1.79]</td><td>1.18 [0.96, 1.44]</td><td>1.14 [0.93, 1.39]</td></tr><tr><td colspan="7">Age</td></tr><tr><td> 18&#8211;30</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr><tr><td> 31&#8211;40</td><td>1.08 [0.75, 1.55]</td><td>1.30 [0.92, 1.83]</td><td>0.95 [0.67, 1.35]</td><td>0.97 [0.68, 1.36]</td><td>1.02 [0.72, 1.44]</td><td>1.12 [0.79, 1.59]</td></tr><tr><td> 41&#8211;50</td><td>1.10 [0.77, 1.58]</td><td>1.25 [0.89, 1.75]</td><td>0.99 [0.71, 1.39]</td><td>0.92 [0.66, 1.28]</td><td>1.06 [0.76, 1.48]</td><td>1.21 [0.87, 1.70]</td></tr><tr><td> 51&#8211;60</td><td>2.03 [1.37, 3.00]</td><td>2.05 [1.45, 2.89]</td><td>1.63 [1.15, 2.30]</td><td>1.69 [1.21, 2.36]</td><td>1.38 [0.98, 1.93]</td><td>1.80 [1.29, 2.52]</td></tr><tr><td> 61&#8211;70</td><td>1.65 [1.13, 2.41]</td><td>2.06 [1.44, 2.94]</td><td>1.49 [1.04, 2.14]</td><td>1.81 [1.29, 2.55]</td><td>1.35 [0.95, 1.92]</td><td>2.09 [1.47, 3.00]</td></tr><tr><td> 71&#8211;80</td><td>1.86 [1.07, 3.22]</td><td>2.57 [1.57, 4.20]</td><td>1.46 [0.93, 2.31]</td><td>1.84 [1.16, 2.95]</td><td>1.12 [0.71, 1.77]</td><td>2.33 [1.49, 3.64]</td></tr><tr><td> 80+</td><td>1.49 [0.70, 3.17]</td><td>1.29 [0.69, 2.45]</td><td>1.18 [0.61, 2.28]</td><td>2.05 [1.02, 4.11]</td><td>1.30 [0.67, 2.53]</td><td>2.83 [1.44, 5.58]</td></tr><tr><td colspan="7">Ethnicity</td></tr><tr><td> White</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr><tr><td> Black</td><td>0.87 [0.60, 1.26]</td><td>0.77 [0.55, 1.07]</td><td>0.81 [0.58, 1.13]</td><td>1.03 [0.74, 1.43]</td><td>0.67 [0.48, 0.93]</td><td>0.86 [0.61, 1.21]</td></tr><tr><td> Asian or Pacific Islander</td><td>0.92 [0.42, 2.00]</td><td>0.53 [0.27, 1.05]</td><td>0.45 [0.26, 0.81]</td><td>0.59 [0.28, 1.23]</td><td>0.47 [0.25, 0.89]</td><td>0.83 [0.42, 1.63]</td></tr><tr><td> Other</td><td>1.22 [0.79, 1.88]</td><td>1.07 [0.71, 1.62]</td><td>1.61 [1.04, 2.50]</td><td>1.49 [0.99, 2.23]</td><td>1.42 [0.94, 2.13]</td><td>1.80 [1.19, 2.72]</td></tr><tr><td colspan="7">Income</td></tr><tr><td> &lt;$15,000</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr><tr><td> $15,000&#8211;$34,999</td><td>0.87 [0.58, 1.30]</td><td>1.21 [0.83, 1.77]</td><td>1.22 [0.84, 1.76]</td><td>1.41 [0.98, 2.03]</td><td>0.91 [0.63, 1.33]</td><td>0.97 [0.67, 1.41]</td></tr><tr><td> $35,000&#8211;$49,999</td><td>1.09 [0.69, 1.73]</td><td>1.09 [0.72, 1.66]</td><td>1.05 [0.69, 1.59]</td><td>1.17 [0.77, 1.78]</td><td>0.96 [0.63, 1.45]</td><td>0.77 [0.51, 1.18]</td></tr><tr><td> $50,000+</td><td>0.98 [0.67, 1.45]</td><td>1.12 [0.78, 1.61]</td><td>0.97 [0.68, 1.39]</td><td>1.42 [0.99, 2.04]</td><td>0.93 [0.65, 1.34]</td><td>0.95 [0.66, 1.37]</td></tr><tr><td> Missing</td><td>1.43 [0.82, 2.49]</td><td>2.16 [1.29, 3.60]</td><td>1.14 [0.71, 1.85]</td><td>2.59 [1.58, 4.24]</td><td>1.36 [0.81, 2.26]</td><td>1.43 [0.87, 2.35]</td></tr><tr><td colspan="7">Education</td></tr><tr><td> High school or less</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr><tr><td> Some college</td><td>1.47 [1.12, 1.95]</td><td>1.24 [0.96, 1.59]</td><td>1.12 [0.87, 1.44]</td><td>1.15 [0.89, 1.47]</td><td>0.92 [0.71, 1.18]</td><td>1.00 [0.78, 1.28]</td></tr><tr><td> College graduate</td><td>1.70 [1.23, 2.40]</td><td>1.60 [1.18, 2.15]</td><td>1.63 [1.21, 2.19]</td><td>1.24 [0.92, 1.65]</td><td>1.03 [0.78, 1.37]</td><td>1.02 [0.76, 1.37]</td></tr><tr><td> Graduate school</td><td>1.99 [1.28, 3.11]</td><td>1.57 [1.06, 2.31]</td><td>2.54 [1.71, 3.79]</td><td>1.57 [1.08, 2.28]</td><td>1.17 [0.81, 1.68]</td><td>0.92 [0.63, 1.32]</td></tr><tr><td colspan="7">Patient activation</td></tr><tr><td> Level 1</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr><tr><td> Level 2</td><td>1.33 [0.86, 2.08]</td><td>1.62 [1.08, 2.44]</td><td>1.06 [0.70, 1.60]</td><td>1.13 [0.74, 1.70]</td><td>1.47 [0.97, 2.22]</td><td>0.92 [0.61, 1.38]</td></tr><tr><td> Level 3</td><td>1.42 [0.95, 2.12]</td><td>1.65 [1.14, 2.38]</td><td>1.05 [0.71, 1.54]</td><td>1.25 [0.86, 1.83]</td><td>1.53 [1.04, 2.24]</td><td>1.04 [0.71, 1.51]</td></tr><tr><td> Level 4</td><td>2.13 [1.43, 3.18]</td><td>2.02 [1.41, 2.91]</td><td>1.50 [1.00, 2.13]</td><td>1.17 [0.81, 1.71]</td><td>1.82 [1.25, 2.66]</td><td>1.31 [0.97, 2.05]</td></tr><tr><td colspan="7">Self-rated health</td></tr><tr><td> Poor</td><td>1.35 [0.62, 2.93]</td><td>1.80 [0.88, 3.66]</td><td>1.39 [0.68, 2.82]</td><td>2.93 [1.51, 5.69]</td><td>1.51 [0.73, 3.13]</td><td>1.95 [0.95, 4.00]</td></tr><tr><td> Fair</td><td>1.41 [0.88, 2.28]</td><td>1.13 [0.73, 1.74]</td><td>0.99 [0.64, 1.52]</td><td>1.22 [0.81, 1.85]</td><td>0.91 [0.59, 1.41]</td><td>0.82 [0.53, 1.25]</td></tr><tr><td> Good</td><td>1.37 [0.93, 2.03]</td><td>0.80 [0.56, 1.12]</td><td>0.89 [0.62, 1.26]</td><td>0.87 [0.62, 1.23]</td><td>0.81 [0.57, 1.15]</td><td>0.67 [0.48, 0.95]</td></tr><tr><td> Very good</td><td>1.40 [0.95, 2.05]</td><td>0.87 [0.61, 1.23]</td><td>1.03 [0.73, 1.45]</td><td>1.09 [0.78, 1.52]</td><td>0.85 [0.60, 1.19]</td><td>0.79 [0.56, 1.11]</td></tr><tr><td> Excellent</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr><tr><td colspan="7">Chronic conditions</td></tr><tr><td> 0</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr><tr><td> 1</td><td>0.99 [0.74, 1.34]</td><td>1.17 [0.90, 1.55]</td><td>1.17 [0.88, 1.54]</td><td>0.95 [0.72, 1.25]</td><td>1.19 [0.98, 1.69]</td><td>0.98 [0.74, 1.29]</td></tr><tr><td> 2+</td><td>1.34 [0.99, 1.82]</td><td>1.32 [1.00, 1.72]</td><td>1.36 [1.04, 1.79]</td><td>1.16 [0.90, 1.51]</td><td>1.62 [1.25, 2.11]</td><td>1.14 [0.88, 1.49]</td></tr></table>
ac2b6fed540529f7f36278a6b21860f37d75c6bfcec9d0d254784ea025e39e46.png
complex
<table><tr><td>Antibiotic class</td><td>Multidrug-resistant (n = 226)</td><td>Non-multidrug-resistant (n = 514)</td><td><i>P</i>-value</td></tr><tr><td>Aminoglycosides</td><td>226 (29.2%)</td><td>505 (91.1%)</td><td>&lt;0.001</td></tr><tr><td>Antipseudomonal carbapenems</td><td>226 (15.0%)</td><td>508 (84.6%)</td><td>&lt;0.001</td></tr><tr><td>Antipseudomonal cephalosporins</td><td>226 (26.5%)</td><td>504 (93.7%)</td><td>&lt;0.001</td></tr><tr><td>Antipseudomonal fluoroquinolones</td><td>222 (21.5%)</td><td>502 (88.4%)</td><td>&lt;0.001</td></tr><tr><td>Antipseudomonal penicillins +</td><td rowspan="2">221 (22.2%)</td><td rowspan="2">502 (89.0%)</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#946;-lactamase inhibitors</td></tr><tr><td>Monobactams</td><td>158 (13.9%)</td><td>208 (81.2%)</td><td>&lt;0.001</td></tr><tr><td>Phosphonic acids</td><td>86 (40.7%)</td><td>105 (81.0%)</td><td>&lt;0.001</td></tr><tr><td>Polymyxins</td><td>159 (97.5%)</td><td>215 (92.1%)</td><td>0.025</td></tr></table>
53e1b1700650b72ce62c9f903aff6784642ee82ff9ab44bd02b4c48142c1ec67.png
simple
<table><tr><td>Variable</td><td>No. of missing data</td></tr><tr><td>Expenditure</td><td>2</td></tr><tr><td>Family support</td><td>2</td></tr><tr><td>MBI at admission</td><td>10</td></tr><tr><td>WHOQOL-BREF at admission</td><td>15</td></tr><tr><td>Number of joints with limited ROM at admission</td><td>50</td></tr><tr><td>MBI at discharge</td><td>8</td></tr><tr><td>WHOQOL-BREF at discharge</td><td>12</td></tr><tr><td>Number of joints with limited ROM at discharge</td><td>18</td></tr><tr><td>Work status after discharge</td><td>4</td></tr></table>
47f8e6ab0d6218487626a38d089a201bdd9ce2254c4c66b89443bc52375d3b88.png
complex
<table><tr><td>Name</td><td>Forward</td><td>Reverse</td><td>Accession number</td><td>Transcripts length (base pairs)</td><td>Primer efficiency (%)</td></tr><tr><td colspan="6">Housekeeping gene study</td></tr><tr><td> <i>Actb</i></td><td>agccatgtacgtagccatcc</td><td>accctcatagatgggcacag</td><td>NM_031144.3</td><td>115</td><td>100.8</td></tr><tr><td> <i>Gapdh</i></td><td>gtgatgctggtgctgagta</td><td>gcggaaggggcggagatg</td><td>NM_017008.4</td><td>115</td><td>77.2</td></tr><tr><td> <i>Hmbs</i></td><td>aggatgggcaactgtacctg</td><td>aactgtgggtcatcctctgg</td><td>NM_013168.2</td><td>130</td><td>85.1</td></tr><tr><td> <i>Hprt1</i></td><td>gcagactttgctttccttgg</td><td>agaggtccttttcaccagca</td><td>NM_012583.2</td><td>79</td><td>86.3</td></tr><tr><td> <i>Ppia</i></td><td>catcctgaagcatacaggtc</td><td>catccagccactcagtctt</td><td>NM_017101.1</td><td>107</td><td>98.7</td></tr><tr><td> <i>Ppib</i></td><td>caagacctcctggctagacg</td><td>ttctccaccttccgtaccac</td><td>NM_022536.2</td><td>81</td><td>87.6</td></tr><tr><td> <i>Rpl13a</i></td><td>gatgaacaccaacccgtctc</td><td>atcccatccaacaccttgag</td><td>NM_173340.2</td><td>141</td><td>90.5</td></tr><tr><td> <i>Sdha</i></td><td>cgagatccgtgaaggaagag</td><td>ctctgagatcccaggcagac</td><td>NM_130428.1</td><td>109</td><td>90.0</td></tr><tr><td colspan="6">Gene expression study</td></tr><tr><td> <i>Ppib</i><sup>a</sup></td><td>caagacctcctggctagacg</td><td>ttctccaccttccgtaccac</td><td>NM_022536.2</td><td>81</td><td>98.9</td></tr><tr><td> <i>Rpl13a</i><sup>a</sup></td><td>gatgaacaccaacccgtctc</td><td>atcccatccaacaccttgag</td><td>NM_173340.2</td><td>141</td><td>98.9</td></tr><tr><td> <i>Adamts4</i></td><td>aactccctgttccccagact</td><td>tagcttcagggccaggtaga</td><td>NM_023959.1</td><td>271</td><td>91.4</td></tr><tr><td> <i>Mmp9</i></td><td>cactgtaactgggggcaact</td><td>cacttcttgtcagcgtcgaa</td><td>NM_031055.1</td><td>150</td><td>103.8</td></tr><tr><td> <i>Plat</i></td><td>tctgccgcccactgctttg</td><td>cgaatgtctgctcctcctctcc</td><td>NM_013151.2</td><td>103</td><td>106.7</td></tr><tr><td> <i>Serpin1</i></td><td>atgaggctggtggcatctac</td><td>gatcagctgtggtttgagca</td><td>NM_053779.1</td><td>131</td><td>99.8</td></tr><tr><td> <i>Timp1</i></td><td>ggttccctggcataatctga</td><td>atggctgaacagggaaacac</td><td>NM_053819.1</td><td>99</td><td>101.2</td></tr><tr><td> <i>Timp3</i></td><td>gctgtgcaactttgtggaga</td><td>aattgcaacccaggtggtag</td><td>NM_012886.2</td><td>86</td><td>93.6</td></tr></table>
49343c92f6814621872ffc73bf448a5085dc9c4d27132adffe1f266536054984.png
complex
<table><tr><td rowspan="2">Response</td><td colspan="2">Medical <i>n</i> = 779</td><td colspan="2">Dental <i>n</i> = 347</td><td rowspan="2"><i>P</i> value</td></tr><tr><td>Mean (SD)</td><td>Med (IOR)</td><td>Mean (SD)</td><td>Med (IQR)</td></tr><tr><td>My muscles become tense</td><td>1.88 (0.89)</td><td>2.0 (1)</td><td>1.99 (0.88)</td><td>2.0 (1)</td><td>0.027</td></tr><tr><td>My breathing rate increases</td><td>1.85 (0.90)</td><td>2.0 (1)</td><td>1.72 (0.85)</td><td>1.0 (1)</td><td>0.030</td></tr><tr><td>I perspire</td><td>1.53 (0.81)</td><td>1.0 (1)</td><td>1.50 (0.77)</td><td>1.0 (1)</td><td>0.616</td></tr><tr><td>I feel nauseated and sick to my stomach</td><td>1.48 (0.79)</td><td>1.0 (1)</td><td>1.27 (0.60)</td><td>1.0 (0)</td><td>0.000</td></tr><tr><td>My heart beats faster</td><td>2.07 (0.99)</td><td>2.0 (2)</td><td>1.83 (0.86)</td><td>2.0 (1)</td><td>0.000</td></tr></table>
9a17756020cd8aad583b5c835d1aadcd044ccbec2df95e6a3ce053183ee33860.png
simple
<table><tr><td>genes percontig</td><td>number ofcontigs</td><td>contigs perscaffold</td><td>number ofscaffolds</td><td><i>Vitis </i>genes perdeleted block</td><td>number ofdeletions</td></tr><tr><td>1</td><td>1699</td><td>1</td><td>469</td><td>1</td><td>2253</td></tr><tr><td>2</td><td>612</td><td>2</td><td>181</td><td>2</td><td>548</td></tr><tr><td>3</td><td>337</td><td>3</td><td>121</td><td>3</td><td>167</td></tr><tr><td>4</td><td>210</td><td>4</td><td>80</td><td>4</td><td>36</td></tr><tr><td>5</td><td>140</td><td>5</td><td>67</td><td>5</td><td>23</td></tr><tr><td>6</td><td>107</td><td>6</td><td>29</td><td>6</td><td>8</td></tr><tr><td>7</td><td>91</td><td>7</td><td>25</td><td>7</td><td>5</td></tr><tr><td>8</td><td>55</td><td>8</td><td>19</td><td>8</td><td>1</td></tr><tr><td>9</td><td>38</td><td>9</td><td>27</td><td>9</td><td>1</td></tr><tr><td>10</td><td>36</td><td>10</td><td>10</td><td>10</td><td>0</td></tr><tr><td>&gt;10</td><td>289</td><td>&gt;10</td><td>59</td><td>&gt;10</td><td>3</td></tr><tr><td>total: 14033</td><td>3614</td><td>total: 3614</td><td>1087</td><td>total: 4267</td><td>3045</td></tr></table>
07c54ace43af6d3c6682c6611a0a9bd314325892fe1e296b3604c9d4dfe2b1b0.png
complex
<table><tr><td></td><td colspan="2">Number of OTU</td><td colspan="3">The Mean Proportion of OTUs in the Group (%)</td><td></td><td></td></tr><tr><td>Taxon</td><td>Moderate exposure</td><td>Low exposure</td><td>Moderate exposure <sup>a</sup></td><td>Low exposure <sup>a</sup></td><td><i>p</i>-value <sup>a</sup></td><td>Odds ratio <sup>b</sup></td><td>95% CI <sup>b</sup></td></tr><tr><td><i>Actinobacteria /Actinomyces</i></td><td>912</td><td>906</td><td>5.5%</td><td>5.0%</td><td>0.90</td><td>0.96</td><td>0.87&#8211;1.06</td></tr><tr><td><i>Actinobacteria /Rothia</i></td><td>326</td><td>415</td><td>1.6%</td><td>2.4%</td><td>0.15</td><td>0.75</td><td>0.64&#8211;0.87</td></tr><tr><td><i>Bacteroidetes /Porphyromonas</i></td><td>609</td><td>640</td><td>2.7%</td><td>3.7%</td><td>0.46</td><td>0.91</td><td>0.81&#8211;1.02</td></tr><tr><td><i>Bacteroidetes /Prevotella</i></td><td>2344</td><td>2497</td><td>14.4%</td><td>12.7%</td><td>0.80</td><td>0.89</td><td>0.83&#8211;0.94</td></tr><tr><td><i>Bacteroidetse /Prevotellaceae</i></td><td>202</td><td>484</td><td>0.9%</td><td>2.4%</td><td>0.19</td><td>0.39</td><td>0.33&#8211;0.47</td></tr><tr><td><i>Firmicutes</i></td><td>353</td><td>251</td><td>1.7%</td><td>1.3%</td><td>0.45</td><td>1.35</td><td>1.14&#8211;1.59</td></tr><tr><td><i>Firmicutes /Bacilli</i></td><td>3910</td><td>3884</td><td>19.1%</td><td>21.2%</td><td>0.62</td><td>0.95</td><td>0.91&#8211;1.00</td></tr><tr><td><i>Firmicutes /Gemella</i></td><td>712</td><td>552</td><td>4.0%</td><td>3.1%</td><td>0.76</td><td>1.24</td><td>1.11&#8211;1.39</td></tr><tr><td><i>Firmicutes /Lactobacillales</i></td><td>347</td><td>267</td><td>1.8%</td><td>1.4%</td><td>0.63</td><td>1.25</td><td>1.06&#8211;1.47</td></tr><tr><td><i>Firmicutes /Streptococcus</i></td><td>865</td><td>478</td><td>6.0%</td><td>2.3%</td><td>0.11</td><td>1.76</td><td>1.57&#8211;1.97</td></tr><tr><td><i>Firmicutes /Veillonella</i></td><td>1269</td><td>1217</td><td>8.0%</td><td>6.3%</td><td>0.52</td><td>1.00</td><td>0.92&#8211;1.08</td></tr><tr><td><i>Fusobacteria /Fusobacterium</i></td><td>540</td><td>713</td><td>2.6%</td><td>4.0%</td><td>0.11</td><td>0.72</td><td>0.64&#8211;0.80</td></tr><tr><td><i>Fusobacteria /Leptotrichia</i></td><td>810</td><td>744</td><td>4.1%</td><td>3.5%</td><td>0.74</td><td>1.04</td><td>0.94&#8211;1.15</td></tr><tr><td><i>Proteobacteria /Gammaproteobacteria</i></td><td>964</td><td>969</td><td>4.6%</td><td>5.3%</td><td>0.64</td><td>0.95</td><td>0.86&#8211;1.04</td></tr><tr><td><i>Proteobacteria /Neisseria</i></td><td>493</td><td>317</td><td>2.2%</td><td>1.8%</td><td>0.65</td><td>1.50</td><td>1.29&#8211;1.73</td></tr><tr><td><i>Proteobacteria /Neisseriaceae</i></td><td>2930</td><td>3190</td><td>14.6%</td><td>19.8%</td><td>0.43</td><td>0.86</td><td>0.82&#8211;0.91</td></tr><tr><td><i>Proteobacteria/Pasteurellaceae</i></td><td>1311</td><td>542</td><td>6.2%</td><td>3.5%</td><td>0.34</td><td>2.39</td><td>2.15&#8211;2.64</td></tr></table>
8b77a0484bdc5109b35b2558e07ff208df3c2f80ee74712cbbf8fb9c11d19f9a.png
simple
<table><tr><td>Primers</td><td>Sequences</td><td>Nucleotide position</td></tr><tr><td></td><td>First round</td><td></td></tr><tr><td>Sense</td><td>5&#8242;-TTCATACAGTAACGCCCAGC-3&#8242;</td><td>259&#8211;278</td></tr><tr><td>Antisense</td><td>5&#8242;-GCAACTACAGGGATTGTAAGGG-3&#8242;</td><td>808&#8211;829</td></tr><tr><td></td><td>Second round</td><td></td></tr><tr><td>Sense</td><td>5&#8242;GCCTTGTGTTTCTATGTTTGC-3&#8242;</td><td>277&#8211;297</td></tr><tr><td>Antisense</td><td>5&#8242;GCATCCATACATTCTGCGAG-3&#8242;</td><td>786&#8211;805</td></tr></table>
3f1573908d74d1dbe09da84fc9a246ac1971ea4bd1d26cf0981da4dc632ab5dc.png
complex
<table><tr><td></td><td></td><td></td><td colspan="2">(% completing step correctly) (n = 15)</td><td></td></tr><tr><td></td><td></td><td>Description of step</td><td>End of training<sup>a</sup></td><td>7 months post training<sup>b</sup></td><td>Most common error(s)</td></tr><tr><td>1</td><td></td><td>Work surface disinfected with alcohol</td><td>-</td><td>-</td><td>Not applicable due to change in training protocol.</td></tr><tr><td>2</td><td></td><td>Assembles all required equipment</td><td>87</td><td>100</td><td></td></tr><tr><td>3</td><td>S</td><td>Put on new pair of gloves</td><td>93</td><td>93</td><td></td></tr><tr><td>4</td><td></td><td>Check expiry date of RDT packet</td><td>67</td><td>80</td><td>Did not check.</td></tr><tr><td>5</td><td></td><td>Check desiccant sachet is dry</td><td>100</td><td>67</td><td>Did not check.</td></tr><tr><td>6</td><td></td><td>Write client name on cassette</td><td>80</td><td>93</td><td></td></tr><tr><td>7</td><td></td><td>Place cassette on level surface</td><td>100</td><td>100</td><td></td></tr><tr><td>8</td><td>S</td><td>Clean finger with alcohol swab</td><td>93</td><td>93</td><td></td></tr><tr><td>9</td><td></td><td>Allow finger to dry before pricking</td><td>100</td><td>93</td><td></td></tr><tr><td>10</td><td>S</td><td>Use sterile lancet to prick finger</td><td>93</td><td>93</td><td>Set down sterile lancet onto surface after removing cap</td></tr><tr><td>11</td><td></td><td>Puncture side of ball of the 3rd or 4th finger</td><td>100</td><td>73</td><td>Punctured vertically (i.e. perpendicular to the tip)</td></tr><tr><td>12</td><td>S</td><td>Dispose of lancet immediately after pricking finger</td><td>100</td><td>87</td><td>Used lancet, then set down onto work surface</td></tr><tr><td>13</td><td></td><td>Wipes away initial blood from finger</td><td>100</td><td>93</td><td></td></tr><tr><td>14</td><td>A</td><td>Uses blood collection device correctly</td><td>100</td><td>100</td><td></td></tr><tr><td>15</td><td>A</td><td>Correctly transfer blood to cassette using tool</td><td>100</td><td>100</td><td></td></tr><tr><td>16</td><td>S</td><td>Dispose of blood collection tool immediately</td><td>100</td><td>87</td><td>Left blood collection device inserted into sample well.</td></tr><tr><td>17</td><td>A</td><td>Dispenses correct volume of buffer</td><td>87</td><td>60</td><td>Too much buffer added.</td></tr><tr><td>18</td><td>A</td><td>Start the timer immediately after adding buffer</td><td>87</td><td>60</td><td>Did not record time.</td></tr><tr><td>19</td><td></td><td>Dispose of non-sharps safely</td><td>93</td><td>100</td><td></td></tr><tr><td>20a</td><td>A</td><td>States the correct time to read RDT (RDT test sheet)</td><td>100</td><td>-</td><td></td></tr><tr><td>20b</td><td>A</td><td>Waits correct time before reading RDT result</td><td>-</td><td>27</td><td>Waited &lt;5 minutes before reading result.</td></tr><tr><td>21</td><td>A</td><td>Reads test results correctly <sup>c</sup></td><td>80</td><td>100</td><td></td></tr><tr><td>22</td><td>T</td><td>Completes correct sections of treatment register</td><td>87</td><td>93</td><td></td></tr><tr><td>23</td><td>T</td><td>Selects appropriate AL dose based on weight</td><td>87</td><td>100</td><td>Did not record time.</td></tr><tr><td>24</td><td>T</td><td>Selects appropriate paracetamol dose</td><td>60</td><td>93</td><td></td></tr><tr><td>25</td><td>T</td><td>Selects correct Parent Information sheet for AL dose</td><td>67</td><td>40</td><td></td></tr><tr><td>26</td><td>T</td><td>States correct time for 2nd dose of AL to be taken</td><td>47</td><td>40</td><td>Did not complete information sheet, provided counselling verbally only</td></tr></table>
434dfaa2fe26fb6ad7ca4d5311810ba7652c389713a5d0330eac8c0311e06f85.png
simple
<table><tr><td>Intervention</td><td>n</td><td>Duration</td><td>% of analyzed time</td></tr><tr><td>Respiratory support via mask</td><td>46</td><td>8.8 (1.5-28.5) min</td><td>46.9 (15.8-97.6)<sup>b</sup></td></tr><tr><td> Sustained inflations</td><td>15</td><td>8.5 (1.8&#8211;13.8) s</td><td>2.6(0.2-8.4)<sup>c</sup></td></tr><tr><td> Mechanical ventilation</td><td>7</td><td>53.1 (6.9-128.5) s</td><td>11.6(0.5-69.8)<sup>c</sup></td></tr><tr><td>Suctioning</td><td>31</td><td>34.6 (0.9-153.6) s</td><td>3.2(0.1-8.7)<sup>b</sup></td></tr><tr><td>CPAP prior to nasopharyngeal tube</td><td>12</td><td>22.6 (10-39.4) min<sup>c</sup></td><td> </td></tr><tr><td>Stabilization prior to transport</td><td>22</td><td>27.3 (11.7-50) min<sup>d</sup></td><td> </td></tr></table>
7f5bed28e756aa7a7cf1fb62724fa7e79e21f35672f5ff3a66f1c31e28ab4f1e.png
simple
<table><tr><td>Patients with total lipid profile</td><td>All patients (n = 2,009)</td><td>Very high risk* (n = 1,649)</td><td>High Risk (n = 58)</td><td>Moderate risk (n = 214)</td><td>Low Risk (n = 88)</td></tr><tr><td>LDL-C not at target [%]<sup>&#8224;</sup></td><td>61.8</td><td>69.5</td><td>56.9</td><td>29.0</td><td><i><sup>&#916;</sup></i></td></tr><tr><td>Low HDL-C (&lt;1.0 [men]/1.2 [women] mmol/L) [%]</td><td>55.5</td><td>58.4</td><td>36.2</td><td>47.2</td><td>33.0</td></tr><tr><td>Elevated TG (&gt;1.7 mmol/L) [%]</td><td>48.5</td><td>51.1</td><td>37.9</td><td>36.4</td><td>37.5</td></tr><tr><td>All patients</td><td>(n = 2,181)</td><td>(n = 1,801)</td><td>(n = 59)</td><td>(n = 224)</td><td>(n= 97)</td></tr><tr><td>LDL-C not at target [%]<sup>&#8224;,&#8225;</sup></td><td>61.5</td><td>69.5</td><td>56.9</td><td>29.0</td><td><i><sup>&#916;</sup></i></td></tr><tr><td>Low HDL-C (&lt;1.0 [men]/1.2 [women] mmol/L) [%]<sup>&#8225;</sup></td><td>56.8</td><td>59.8</td><td>37.3</td><td>47.8</td><td>33.7</td></tr><tr><td>Elevated TG (&gt;1.7 mmol/L) [%]<sup><i>&#167;</i></sup></td><td>46.7</td><td>48.6</td><td>37.3</td><td>37.5</td><td>39.6</td></tr></table>
c507f2a413a100a82451dca7a3cea9d8e10117621d877632cd65f7d7a4bab2a4.png
simple
<table><tr><td>Year</td><td>Month</td><td>BMI</td><td>Treatment</td><td>Dose</td><td>Performance status</td></tr><tr><td>2011</td><td></td><td>31.2</td><td></td><td></td><td></td></tr><tr><td>2013</td><td>Feb</td><td>29.4</td><td>FLOX C1</td><td>Oxaliplatin: 150 mg Fluorouracil: 950 mg Calciumfolinat: 110 mg</td><td>0</td></tr><tr><td></td><td>March</td><td>28.7</td><td>FLOX C2</td><td>Oxaliplatin: 140 mg Fluorouracil: 900 mg Calciumfolinat: 100 mg</td><td>1</td></tr><tr><td></td><td>April</td><td>27.8</td><td>FLOX C3</td><td>Oxaliplatin: 120 mg Fluorouracil: 720 mg Calciumfolinat: 100 mg</td><td>1</td></tr><tr><td></td><td>June</td><td>29.2</td><td>Capecitabine</td><td>500mgx1</td><td>1-2</td></tr><tr><td></td><td>July</td><td></td><td>Capecitabine/ Bevacizumab C1</td><td>500 mg &#215; 2/ 350 mg</td><td>1-2</td></tr><tr><td></td><td>Aug</td><td></td><td>Capecitabine/ Bevacizumab C2</td><td>500 mg &#215; 2/ 350 mg</td><td>0-1</td></tr><tr><td></td><td></td><td></td><td>Capecitabine/ Bevacizumab C3</td><td>500 mg &#215; 2/ 350 mg</td><td></td></tr><tr><td></td><td>Sept</td><td></td><td>Capecitabine/ Bevacizumab C4</td><td>500 mg &#215; 2/ 350 mg</td><td></td></tr><tr><td></td><td></td><td></td><td>Capecitabine/ Bevacizumab C5</td><td>500 mg &#215; 2/ 350 mg</td><td></td></tr><tr><td></td><td>Oct</td><td>29.8</td><td>Capecitabine/ Bevacizumab C6</td><td>500 mg &#215; 2/ 350 mg</td><td>0-1</td></tr><tr><td></td><td></td><td></td><td>Capecitabine/ Bevacizumab C7</td><td>500 mg &#215; 2/ 350 mg</td><td></td></tr><tr><td>2014</td><td>Jan</td><td>31.2</td><td></td><td></td><td>0</td></tr></table>
da570045c0cee8953be2362401ba0333aab80623e8e1d0f73fb758a8d36b918d.png
simple
<table><tr><td>Disc level</td><td>Overall</td><td>Men</td><td>Women</td></tr><tr><td>L1-L2</td><td>21.9 &#177; 3.8</td><td>21.6 &#177; 3.9</td><td>22.1 &#177; 3.8</td></tr><tr><td>L2-L3</td><td>24.0 &#177; 4.5</td><td>24.4 &#177; 4.6</td><td>23.7 &#177; 4.5</td></tr><tr><td>L3-L4</td><td>26.2 &#177; 5.5</td><td>26.5 &#177; 5.0</td><td>26.0 &#177; 5.7</td></tr><tr><td>L4-L5</td><td>26.9 &#177; 6.5</td><td>27.0 &#177; 6.1</td><td>26.8 &#177; 6.8</td></tr><tr><td>L5-S1</td><td>27.9 &#177; 8.2</td><td>27.4 &#177; 8.6</td><td>28.0 &#177; 8.0</td></tr></table>
2b8953bc0365f0b0a4f17e658a86c9df6a31c984bec6031dbd792be028c0b5e4.png
complex
<table><tr><td rowspan="2"> </td><td colspan="3">Placebo yoghurt group</td><td colspan="3">Plant stanol yoghurt group</td><td rowspan="2">p<sup>b</sup></td></tr><tr><td>Baseline</td><td>Intervention</td><td>Change (%)</td><td>Baseline</td><td>Intervention</td><td>Change (%)</td></tr><tr><td>Total cholesterol (mg/dl)</td><td>233.4 &#177; 26.83</td><td>235.0 &#177; 23.75</td><td>1.2 &#177; 8.11</td><td>241.1 &#177; 25.81</td><td>232.0 &#177; 22.12</td><td>&#8722;3.4 &#177; 7.60</td><td>0.007*</td></tr><tr><td>LDL cholesterol (mg/dl)</td><td>154.5 &#177; 21.16</td><td>154.1 &#177; 18.58</td><td>0.5 &#177; 10.65</td><td>157.9 &#177; 26.40</td><td>147.7 &#177; 24.41</td><td>&#8722;5.8 &#177; 10.90</td><td>0.005*</td></tr><tr><td>HDL cholesterol (mg/dl)</td><td>51.2 &#177; 11.36</td><td>50.6 &#177; 11.62</td><td>&#8722;0.9 &#177; 10.76</td><td>50.1 &#177; 14.35</td><td>49.6 &#177; 15.79</td><td>&#8722;1.2 &#177; 8.87</td><td>0.524</td></tr><tr><td>Triglycerides (mg/dl)</td><td>138.5 &#177; 66.41</td><td>151.6 &#177; 66.45</td><td>19.8 &#177; 53.75</td><td>165.9 &#177; 99.42</td><td>174.0 &#177; 84.62</td><td>11.2 &#177; 27.05</td><td>0.606</td></tr><tr><td>VLDL cholesterol (mg/dl)</td><td>27.7 &#177; 13.27</td><td>30.3 &#177; 13.26</td><td>19.8 &#177; 53.60</td><td>33.1 &#177; 19.88</td><td>34.8 &#177; 16.92</td><td>11.3 &#177; 27.06</td><td>0.596</td></tr><tr><td>Non-HDL cholesterol (mg/dl)</td><td>182.2 &#177; 24.54</td><td>184.4 &#177; 20.86</td><td>2.0 &#177; 12.98</td><td>191.0 &#177; 28.24</td><td>182.5 &#177; 26.45</td><td>&#8722;4.2 &#177; 10.73</td><td>0.005*</td></tr><tr><td>Apolipoprotein A-I (mg/dl)</td><td>155.9 &#177; 20.50</td><td>154.3 &#177; 19.28</td><td>&#8722;0.8 &#177; 6.02</td><td>152.7 &#177; 26.12</td><td>154.4 &#177; 33.25</td><td>1.4 &#177; 13.17</td><td>0.602</td></tr><tr><td>Apolipoprotein B (mg/dl)</td><td>122.1 &#177; 19.92</td><td>121.1 &#177; 20.28</td><td>&#8722;0.4 &#177; 8.72</td><td>128.2 &#177; 20.09</td><td>121.0 &#177; 19.18</td><td>&#8722;5.0 &#177; 11.81</td><td>0.076</td></tr><tr><td>Lipoprotein-a (mg/dl)</td><td>27.8 &#177; 26.86</td><td>29.3 &#177; 27.78</td><td>4.1 &#177; 18.13</td><td>35.8 &#177; 31.18</td><td>32.6 &#177; 29.39</td><td>&#8722;2.8 &#177; 25.36</td><td>0.094</td></tr></table>
5a6d033b54f1eba8c519e71e3dbd4c150e4ee451b8877152ea1a8d5d4595fe76.png
simple
<table><tr><td></td><td>Center 1Southeast</td><td>Center 2Southeast</td><td>Center 3Southeast</td><td>Center 4Southeast</td><td>Center 5South</td><td>Center 6Northeast</td><td>Center 7Center-West</td><td>Total</td></tr><tr><td>DR-absent</td><td>109 (60.6 %)</td><td>118 (45.9 %)</td><td>71 (41.0 %)</td><td>31 (32.6 %)</td><td>89 (49.4 %)</td><td>82 (50.3 %)</td><td>108 (49.5 %)</td><td>608 (48.0 %)</td></tr><tr><td>DR-NP mild</td><td>35 (19.4 %)</td><td>91 (35.4 %)</td><td>53 (30.6 %)</td><td>33 (34.7 %)</td><td>44 (24.4 %)</td><td>42 (25.8 %)</td><td>54 (24.8 %)</td><td>352 (27.8 %)</td></tr><tr><td>DR-NP moderate</td><td>10 (5.6 %)</td><td>12 (4.7 %)</td><td>5 (2.9 %)</td><td>6 (6.3 %)</td><td>8 (4.4 %)</td><td>4 (2.5 %)</td><td>7 (3.2 %)</td><td>52 (4.1 %)</td></tr><tr><td>DR-NP severe</td><td>8 (4.4 %)</td><td>9 (3.5 %)</td><td>4 (2.3 %)</td><td>0 (0.0 %)</td><td>3 (1.7 %)</td><td>4 (2.5 %)</td><td>6 (2.8 %)</td><td>34 (2.7 %)</td></tr><tr><td>DR-proliferative</td><td>14 (7.8 %)</td><td>20 (7.8 %)</td><td>29 (16.8 %)</td><td>18 (19.0 %)</td><td>27 (15.0 %)</td><td>22 (13.5 %)</td><td>29 (13.3 %)</td><td>159 (12.6 %)</td></tr><tr><td>DR-impossible</td><td>4 (2.2 %)</td><td>7 (2.7 %)</td><td>11 (6.4 %)</td><td>7 (7.4 %)</td><td>9 (5.0 %)</td><td>9 (5.5 %)</td><td>14 (6.4 %)</td><td>61 (4.8 %)</td></tr><tr><td>Total retinopathy</td><td>180 (100 %)</td><td>257 (100 %)</td><td>173 (100 %)</td><td>95 (100 %)</td><td>180 (100 %)</td><td>163 (100 %)</td><td>218 (100 %)</td><td>1266 (100 %)</td></tr><tr><td>MAC-apparently absent</td><td>141 (78.3 %)</td><td>201 (78.2 %)</td><td>137 (79.2 %)</td><td>72 (75.8 %)</td><td>144 (80.0 %)</td><td>124 (76.1 %)</td><td>161 (73.9 %)</td><td>980 (77.4 %)</td></tr><tr><td>MAC-apparenlty present</td><td>32 (17.8 %)</td><td>42 (16.4 %)</td><td>14 (8.1 %)</td><td>13 (13.7 %)</td><td>18 (10.0 %)</td><td>25 (15.3 %)</td><td>35 (16.1 %)</td><td>179 (14.1 %)</td></tr><tr><td>MAC-impossible</td><td>7 (3.9 %)</td><td>14 (5.4 %)</td><td>22 (12.7 %)</td><td>10 (10.5 %)</td><td>18 (10.0 %)</td><td>14 (8.6 %)</td><td>22 (10.1 %)</td><td>107 (8.5 %)</td></tr><tr><td>Total maculopathy</td><td>180 (100 %)</td><td>257 (100 %)</td><td>173 (100 %)</td><td>95 (100 %)</td><td>180 (100 %)</td><td>163 (100 %)</td><td>218 (100 %)</td><td>1266 (100 %)</td></tr></table>
c4f0ca79852fcbfd07bd36d721581461ef939b44125b8f8ba4880e78ad6f7eb8.png
simple
<table><tr><td></td><td>11/15/13</td><td>11/20/13</td><td>1/8/14</td><td>5/26/14</td></tr><tr><td>Total T (2&#8211;45 ng/dL)</td><td>337</td><td>281</td><td>230</td><td><i>288</i></td></tr><tr><td>Free T (0.1&#8211;6.4 pg/mL)</td><td></td><td>41.2</td><td>42.4</td><td><i>55.4</i></td></tr><tr><td>DHEA (&lt;1185 mcg/dL)</td><td>117</td><td></td><td></td><td></td></tr><tr><td>DHEA&#8208;S (24&#8211;278 mcg/dL)</td><td>92</td><td></td><td></td><td></td></tr><tr><td>Estradiol (5&#8211;38 pg/mL)</td><td></td><td></td><td>23</td><td></td></tr><tr><td>FSH (0&#8211;14 mIU/mL)</td><td>86.5</td><td></td><td></td><td></td></tr><tr><td>LH (0&#8211;14 mIU/mL)</td><td>42.7</td><td></td><td></td><td></td></tr><tr><td>17&#8208;hydroxyprogesterone (&lt;51 ng/dL)</td><td></td><td></td><td>26</td><td></td></tr><tr><td>Prolactin (&lt;20 ng/mL)</td><td></td><td></td><td>8</td><td></td></tr><tr><td>ACTH (6&#8211;50 pg/dL)</td><td></td><td>9</td><td></td><td></td></tr></table>
6f523ac02ba4799a1c703e1aaed32e8d82bfa26dd685eb185d52df468ae51fca.png
complex
<table><tr><td>Model</td><td>R<sup>2</sup></td><td>AIC</td><td>&#8710;AIC</td><td>Model parameters</td><td>Parameter estimate</td></tr><tr><td colspan="6"><i>Climate variables only &#8211; Above 1300 m</i></td></tr><tr><td rowspan="2">1</td><td rowspan="2">0.50</td><td rowspan="2">&#8722;217.3</td><td rowspan="2">0</td><td>Precipitation &#8211; 6 month lag</td><td>&#8722;0.56</td></tr><tr><td>Precipitation &#8211; 4 mo. Lag</td><td>0.37</td></tr><tr><td rowspan="2">2</td><td rowspan="2">0.48</td><td rowspan="2">&#8722;215.6</td><td rowspan="2">1.7</td><td>Precipitation &#8211; 6 mo. Lag</td><td>&#8722;1.4</td></tr><tr><td>Mean temperature &#8211; 0 mo. lag</td><td>0.83</td></tr><tr><td colspan="6"><i>Climate and crop variable &#8211; Above 1300 m</i></td></tr><tr><td rowspan="2">1</td><td rowspan="2">0.69</td><td rowspan="2">&#8722;232.3</td><td rowspan="2">0</td><td>Maize/Millet harvest &#8211; 0 mo. lag</td><td>0.47</td></tr><tr><td>Nut harvest &#8211; 4 mo. Lag</td><td>0.53</td></tr><tr><td rowspan="2">2</td><td rowspan="2">0.68</td><td rowspan="2">&#8722;231.0</td><td rowspan="2">1.3</td><td>Maize/Millet harvest &#8211; 0 mo. lag</td><td>0.51</td></tr><tr><td>Bean harvest &#8211; 4 + 5 mo. Lag</td><td>0.51</td></tr></table>
bae284b7c8f1cb679ef7beb52a14005d5e173609d8fd95f5a687a9403cc57171.png
simple
<table><tr><td>Indexes</td><td>T1</td><td>T2</td><td>CK</td></tr><tr><td>CH<sub>4</sub> : O<sub>2</sub></td><td>90:10</td><td>99:1</td><td>&#8211;</td></tr><tr><td>Dissolved O<sub>2</sub> (mg l<sup>&#8722;1</sup>)</td><td>3.96 &#177; 0.09</td><td>0.24 &#177; 0.01</td><td>&#8211;</td></tr><tr><td>Methane oxidation activity (&#956;mol g VSS<sup>&#8722;1</sup> day<sup>&#8722;1</sup>)</td><td>640.16 &#177; 88.76</td><td>354.21 &#177; 45.62</td><td>&#8211;</td></tr><tr><td>Denitrification activity (&#956;mol g VSS<sup>&#8722;1</sup> day<sup>&#8722;1</sup>)</td><td></td><td></td><td></td></tr><tr><td>Nitrite consumption rate</td><td>68.39 &#177; 2.90</td><td>46.50 &#177; 6.19</td><td>28.03 &#177; 1.59</td></tr><tr><td>Nitrate consumption rate</td><td>25.50 &#177; 2.33</td><td>13.18 &#177; 2.07</td><td>5.02 &#177; 1.78</td></tr><tr><td>Formaldehyde (&#956;g l<sup>&#8722;1</sup>)</td><td>355.00 &#177; 7.07</td><td>405.00 &#177; 7.07</td><td>19.50 &#177; 0.71</td></tr><tr><td>Citrate (&#956;g l<sup>&#8722;1</sup>)</td><td>350.00 &#177; 14.14</td><td>320.00 &#177; 14.14</td><td>55.00 &#177; 7.07</td></tr><tr><td>Acetate (&#956;g l<sup>&#8722;1</sup>)</td><td>130.00 &#177; 21.21</td><td>150.00 &#177; 0.00</td><td>17.2 &#177; 2.12</td></tr><tr><td>Formate (&#956;g l<sup>&#8722;1</sup>)</td><td>24.70 &#177; 0.71</td><td>27.20 &#177; 1.41</td><td>0.6 &#177; 0.14</td></tr><tr><td>Methanol (&#956;g l<sup>&#8722;1</sup>)</td><td>0.50 &#177; 0.00</td><td>0.55 &#177; 0.07</td><td>0.15 &#177; 0.07</td></tr></table>
de88d800c2e7fa5fa1941ba0ff65d14f47535be5bc1fa3e36d0860f60e320f2c.png
simple
<table><tr><td>Constructs</td><td>mutation</td><td>XMRV p53</td><td>XMRV p58</td></tr><tr><td>pVP62 (WT)</td><td>None</td><td>+</td><td>+</td></tr><tr><td>pVP62&#916;gg0</td><td>_ to A (nt 372)</td><td>-</td><td>-</td></tr><tr><td>pVP62&#916;gg1</td><td>C to AT (nt 382)</td><td>-</td><td>-</td></tr><tr><td>pVP62&#916;gg2</td><td>T to C (nt 370)</td><td>+</td><td>-</td></tr><tr><td>pVP62&#916;gg3</td><td>T to C (nt 341)</td><td>-</td><td>+</td></tr><tr><td>pVP62&#916;gg4</td><td>T to G (nt 354)</td><td>-</td><td>+</td></tr></table>
c6184f15daa3913f151c7da6ad8f876cd55d8a91fda1d96172b3b65e7be2dbbf.png
simple
<table><tr><td>Observed</td><td>Poisson</td><td>Neg. Bin</td><td>ZIP</td><td>ZINB</td><td>PLH</td><td>NBLH</td></tr><tr><td>1705</td><td>183</td><td>1704</td><td>1705</td><td>1705</td><td>1705</td><td>1705</td></tr></table>
46bade67bb528150efd62632cfa155a4bbf42ab14f33762233cbf90940582950.png
complex
<table><tr><td rowspan="2">HAZ or HAZ Difference</td><td colspan="2">Boys</td><td colspan="2">Girls</td></tr><tr><td>FPC1 Score <sup>b</sup></td><td>Adj-FPC2 Score<sup>c</sup></td><td>FPC1 Score<sup>b</sup></td><td>Adj-FPC2 Score<sup>c</sup></td></tr><tr><td> HAZ at enrollment</td><td>&#8722;0.849</td><td>0.292</td><td>&#8722;0.971</td><td>&#8722;0.136<sup>d</sup></td></tr><tr><td> HAZ at 6 months</td><td>&#8722;0.940</td><td>0.100<sup>e</sup></td><td>&#8722;0.982</td><td>&#8722;0.179<sup>d</sup></td></tr><tr><td> HAZ at 12 months</td><td>&#8722;0.996</td><td>&#8722;0.304</td><td>&#8722;1.000</td><td>&#8722;0.350</td></tr><tr><td> HAZ at 18 months</td><td>&#8722;0.980</td><td>&#8722;0.427</td><td>&#8722;0.992</td><td>&#8722;0.459</td></tr><tr><td> HAZ at 24 months</td><td>&#8722;0.979</td><td>&#8722;0.425</td><td>&#8722;0.990</td><td>&#8722;0.467</td></tr><tr><td>Change of HAZ %tiles from birth to age 24 months</td><td>&#8722;0.156<sup>d</sup></td><td>&#8722;0.919</td><td>&#8722;0.047<sup>e</sup></td><td>&#8722;0.794</td></tr><tr><td>Change of HAZ %tiles between age 6 and 18 months</td><td>&#8722;0.062<sup>e</sup></td><td>&#8722;0.905</td><td>&#8722;0.028<sup>e</sup></td><td>&#8722;0.787</td></tr></table>
9b56e83cdad4f4f700a5e853edd83f1cd01088abb2d1e2a1624ff98e83623bb0.png
complex
<table><tr><td>Oil</td><td>Soybean oil</td><td>Soybean oil</td><td>Soybean oil</td><td>Salmon oil</td><td>Salmon oil</td><td>Salmon oil</td><td colspan="3">ANOVA (P)</td></tr><tr><td>Vitamin E (mg/kg)</td><td>25</td><td>250</td><td>2500</td><td>25</td><td>250</td><td>2500</td><td>Vitamin E</td><td>Oil</td><td>Vitamin E x oil</td></tr><tr><td>Initial weight (g)</td><td>314 &#177; 16</td><td>314 &#177; 15</td><td>313 &#177; 14</td><td>314 &#177; 14</td><td>313 &#177; 14</td><td>314 &#177; 14</td><td>0.99</td><td>0.98</td><td>0.99</td></tr><tr><td>Final weight (g)</td><td>428 &#177; 25</td><td>435 &#177; 22</td><td>434 &#177; 26</td><td>442 &#177; 21</td><td>438 &#177; 26</td><td>440 &#177; 19</td><td>0.96</td><td>0.18</td><td>0.71</td></tr><tr><td>Body weight gain (g/d)</td><td>114 &#177; 22</td><td>122 &#177; 13</td><td>120 &#177; 17</td><td>128 &#177; 13</td><td>124 &#177; 18</td><td>126 &#177; 14</td><td>0.91</td><td>0.058</td><td>0.50</td></tr><tr><td>Diet intake (g/d)</td><td>24.0 &#177; 1.3</td><td>24.6 &#177; 1.4</td><td>24.9 &#177; 1.3</td><td>25.7 &#177; 0.9</td><td>25.1 &#177; 1.5</td><td>25.2 &#177; 1.7</td><td>0.82</td><td>0.008</td><td>0.18</td></tr><tr><td>Feed/gain ratio (g/g)</td><td>5.9 &#177; 1.6</td><td>5.5 &#177; 0.5</td><td>5.7 &#177; 0.7</td><td>5.5 &#177; 0.6</td><td>5.5 &#177; 0.5</td><td>5.4 &#177; 0.4</td><td>0.71</td><td>0.25</td><td>0.60</td></tr></table>
d9afa80d5f2f6d5e1273b7e83052358d5870de4aa7d355b5d324926a5f53910a.png
complex
<table><tr><td></td><td>Maternal support</td><td>Paternal support</td></tr><tr><td colspan="3">Physical activity</td></tr><tr><td>All children</td><td>0.37**</td><td>0.36**</td></tr><tr><td>Boys</td><td>0.31**</td><td>0.26*</td></tr><tr><td>Girls</td><td>0.45**</td><td>0.45**</td></tr><tr><td colspan="3">Fruit and vegetable consumption</td></tr><tr><td>All children</td><td>0.35**</td><td>0.13</td></tr><tr><td>Boys</td><td>0.26*</td><td>0.25</td></tr><tr><td>Girls</td><td>0.46**</td><td>0.05</td></tr></table>
95ee3f0cd914a46e1b9828b936b9e0cff4e1c546f7e975f2a9d9d7efe0a70c68.png
simple
<table><tr><td>Patients</td><td>Uniform orthogonal grid</td><td>Uniform tetrahedron mesh</td><td>Nonuniform tetrahedron mesh</td></tr><tr><td>H&amp;N01</td><td> </td><td> </td><td> </td></tr><tr><td> Number of vertices</td><td>936</td><td>992</td><td>1,007</td></tr><tr><td> NCC</td><td>0.8327</td><td>0.8358</td><td>0.8460</td></tr><tr><td> NRMSE</td><td>0.4988</td><td>0.4938</td><td>0.4792</td></tr><tr><td>H&amp;N02</td><td> </td><td> </td><td> </td></tr><tr><td>Number of vertices</td><td>1,040</td><td>990</td><td>1,000</td></tr><tr><td> NCC</td><td>0.9036</td><td>0.9122</td><td>0.9134</td></tr><tr><td> NRMSE</td><td>0.4182</td><td>0.4116</td><td>0.4084</td></tr><tr><td>H&amp;N03</td><td> </td><td> </td><td> </td></tr><tr><td>Number of vertices</td><td>980</td><td>1,000</td><td>998</td></tr><tr><td> NCC</td><td>0.8470</td><td>0.8471</td><td>0.8482</td></tr><tr><td> NRMSE</td><td>0.4748</td><td>0.4743</td><td>0.4722</td></tr><tr><td>H&amp;N04</td><td> </td><td> </td><td> </td></tr><tr><td>Number of vertices</td><td>1,001</td><td>1,000</td><td>1,000</td></tr><tr><td> NCC</td><td>0.7756</td><td>0.7806</td><td>0.8111</td></tr><tr><td> NRMSE</td><td>0.5841</td><td>0.5817</td><td>0.5567</td></tr><tr><td>H&amp;N05</td><td> </td><td> </td><td> </td></tr><tr><td>Number of vertices</td><td>980</td><td>1,000</td><td>995</td></tr><tr><td> NCC</td><td>0.7565</td><td>0.7690</td><td>0.7843</td></tr><tr><td> NRMSE</td><td>0.6278</td><td>0.6092</td><td>0.5712</td></tr></table>
9c67059b6466e6a9637f2756b846967431234806b5aac851df58855088ea36a0.png
complex
<table><tr><td> </td><td colspan="2">Kessounou South</td><td colspan="2">Malanville North</td><td colspan="2">Allada South</td><td colspan="2">Kandi North</td></tr><tr><td>Distance to water for washing nets</td><td colspan="4">&lt; 0.05 km</td><td colspan="4">&gt; 5.0 km</td></tr><tr><td>Assessment visit</td><td>T12</td><td>T18</td><td>T12</td><td>T18</td><td>T12</td><td>T18</td><td>T12</td><td>T18</td></tr><tr><td>n of nets found with any hole (s)</td><td>219</td><td>210</td><td>294</td><td>260</td><td>178</td><td>133</td><td>241</td><td>208</td></tr><tr><td>n (%) of nets with &#8216;rip in the fabric&#8217;</td><td>158 (72)</td><td>142 (68)</td><td>279 (95)</td><td>248 (95)</td><td>133 (75)</td><td>114 (86)</td><td>219 (91)</td><td>178 (86)</td></tr><tr><td>CI 95%</td><td>65.87-77.66</td><td>61.02-73.58</td><td>91.75-96.88</td><td>92.11-97.34</td><td>67.86-80.54</td><td>78.76-90.66</td><td>86.57-93.89</td><td>80.16-89.71</td></tr><tr><td>n (%) of nets with &#8216;rip in the seam&#8217;</td><td>4 (2)</td><td>5 (2)</td><td>3 (1)</td><td>5 (2)</td><td>10 (6)</td><td>3 (2)</td><td>9 (4)</td><td>16 (8)</td></tr><tr><td>CI 95%</td><td>00.71-04.60</td><td>01.02-05.45</td><td>00.35-02.96</td><td>00.82-04.42</td><td>03.08-10.03</td><td>00.77-06.42</td><td>01.98-06.94</td><td>04.79-12.13</td></tr><tr><td>n (%) of nets with &#8216;burn holes&#8217;</td><td>52 (24)</td><td>62 (29)</td><td>9 (3)</td><td>6 (2)</td><td>26 (14)</td><td>11 (8)</td><td>12 (5)</td><td>9 (4)</td></tr><tr><td>CI 95%</td><td>18.59-29.80</td><td>23.77-36.02</td><td>01.62-05.71</td><td>01.06-04.94</td><td>10.17-20.54</td><td>04.68-14.20</td><td>02.87-08.50</td><td>02.29-08.02</td></tr><tr><td>n (%) of nets chewing by rodent</td><td>5 (2)</td><td>2 (1)</td><td>3 (1)</td><td>1 (1)</td><td>9 (5)</td><td>5 (4)</td><td>1 (0)</td><td>5 (2)</td></tr><tr><td>CI 95%</td><td>00.98-05.23</td><td>00.26-03.41</td><td>00.35-02.96</td><td>00.07-02.15</td><td>02.68-09.33</td><td>01.62-08.50</td><td>00.07-02.31</td><td>01.03-05.50</td></tr></table>
2ad8a417c99a96cd61fbaa1f5c8b6a367fc8a80c5a717dac64cea2a718219cd1.png
simple
<table><tr><td></td><td>Standard method</td><td>Locally-based method</td><td>Total</td></tr><tr><td>Period of facility assessments</td><td>March-April, 2010</td><td>July-August, 2010</td><td>March-August, 2010</td></tr><tr><td>Number of survey teams used</td><td>1</td><td>24</td><td>25</td></tr><tr><td>All unique facilities assessed</td><td>11</td><td>24</td><td>24</td></tr><tr><td>Sub-Health Center</td><td>2</td><td>6</td><td>6</td></tr><tr><td>Basic Health Centers</td><td>8</td><td>16</td><td>16</td></tr><tr><td>Comprehensive Health Centers</td><td>1</td><td>2</td><td>2</td></tr><tr><td>All patients observed/interviewed</td><td>94</td><td>216</td><td>310</td></tr><tr><td>All health workers interviewed</td><td>30</td><td>64</td><td>94</td></tr></table>
868abefdd12914208dd07c68bb3ab9e4d4928b88bf7fb8dc06aec0f26ad4da94.png
simple
<table><tr><td>Category</td><td>AML with inv(16) (n = 27)</td><td>AMML without inv(16) * (n = 10)</td><td>Other types of AML * (n = 22)</td></tr><tr><td>Strong</td><td>20</td><td>1</td><td>7</td></tr><tr><td>Weak/Focal</td><td>5</td><td>3</td><td>3</td></tr><tr><td>Negative</td><td>2</td><td>6</td><td>12</td></tr></table>
e93e1e9fcb24d89c160761ca181de5fae89c90c218e2aee494c8b141d068f087.png
complex
<table><tr><td><i>Age (years)</i></td><td colspan="2"><i>Male</i></td><td colspan="2"><i>Female</i></td></tr><tr><td> </td><td>n</td><td><i>%</i></td><td>n</td><td><i>%</i></td></tr><tr><td>7</td><td>4</td><td>40</td><td>4</td><td>40</td></tr><tr><td>8</td><td>6</td><td>60</td><td>3</td><td>30</td></tr><tr><td>9</td><td>0</td><td>0</td><td>3</td><td>30</td></tr><tr><td>Total</td><td>10</td><td>100</td><td>10</td><td>100</td></tr></table>
b3e442effc5d3848daf9db06a44b4c702adfdc771bc6756f699bc2b50b2dfe14.png
complex
<table><tr><td></td><td colspan="2"><i>RQCD1</i> mutant</td><td colspan="5"><i>RQCD1</i> WT</td></tr><tr><td>Mutation</td><td>n</td><td>%</td><td>n</td><td>%</td><td>OR</td><td>95%CI</td><td><i>p</i>-value</td></tr><tr><td><i>BRAF</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WT</td><td>17</td><td>59</td><td>448</td><td>65</td><td>1</td><td></td><td></td></tr><tr><td>V600E</td><td>7</td><td>24</td><td>193</td><td>28</td><td>1.0</td><td>0.4, 2.3</td><td>0.9</td></tr><tr><td>V600K</td><td>5</td><td>17</td><td>44</td><td>6</td><td>3.0</td><td>1.1, 8.5</td><td>0.04</td></tr><tr><td><i>NRAS</i>**</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WT</td><td></td><td>90</td><td></td><td>91</td><td>1</td><td></td><td></td></tr><tr><td>Mutant</td><td></td><td>10</td><td></td><td>9</td><td>0.7</td><td>0.2, 2.5</td><td>0.6</td></tr></table>
90a016de7d07bfa1666515cc65d9e820ca2d901145c0c3833bce798b55ec7552.png
simple
<table><tr><td>Fatty acids</td><td>CB diets</td><td>SF diets</td></tr><tr><td>Palmitic (16:0)</td><td>26.3</td><td>7.9</td></tr><tr><td>Palmitoleic (16:1)</td><td>0.2</td><td>0.1</td></tr><tr><td>Stearic (18:0)</td><td>29.0</td><td>2.3</td></tr><tr><td>Oleic (18:1n-9)</td><td>31.6</td><td>12.5</td></tr><tr><td>Linoleic (18:2n-6)</td><td>10.5</td><td>75.3</td></tr><tr><td><i>&#945;</i>-Linolenic (18:3n-3)</td><td>1.2</td><td>1.1</td></tr><tr><td>SFAs<sup>1</sup></td><td>56.4</td><td>10.7</td></tr><tr><td>MUFAs<sup>2</sup></td><td>31.9</td><td>12.9</td></tr><tr><td>PUFAs</td><td>11.7</td><td>76.4</td></tr><tr><td>PUFA/SFA ratio</td><td>0.21</td><td>7.14</td></tr><tr><td>n-6/n-3 ratio</td><td>8.8</td><td>68.5</td></tr><tr><td>Relative UI</td><td>0.57</td><td>1.67</td></tr></table>
2e17c9658d91f94b80bb6c9f2f141b89dd451420de68a5d7c2388fbbd69c6c11.png
simple
<table><tr><td>Variable</td><td>Hazards ratio</td><td>95% CI*</td><td><i>P</i> value</td></tr><tr><td>Age (&gt;45.89 vs. &#8804;45.89)</td><td>3.14</td><td>1.58&#8211;6.25</td><td>0.001</td></tr><tr><td>Clinical stage (III-IV vs. I-II)</td><td>3.27</td><td>1.00&#8211;10.67</td><td>0.050</td></tr><tr><td>Relapse (Yes vs. No)</td><td>5.97</td><td>3.10&#8211;11.49</td><td>0.000</td></tr><tr><td>p53R2 expression (High vs. Low)</td><td>0.39</td><td>0.18&#8211;0.85</td><td>0.018</td></tr></table>
df5c499ad8911c2841118b0a5036479cc18663351cd4bbdd910c215def0cf34b.png
complex
<table><tr><td></td><td>Number of patients (%) (<i>N</i> = 36)</td></tr><tr><td colspan="2">Age</td></tr><tr><td> Median (range)</td><td>58 (21&#8211;74)</td></tr><tr><td>&#8805; 65 years</td><td>10 (27.8%)</td></tr><tr><td colspan="2">Sex</td></tr><tr><td> Male</td><td>33 (91.7%)</td></tr><tr><td> Female</td><td>3 (8.3%)</td></tr><tr><td colspan="2">Hepatocellular carcinoma etiology</td></tr><tr><td> Hepatitis B</td><td>26 (72.2%)</td></tr><tr><td> Hepatitis C</td><td>1 (2.8%)</td></tr><tr><td> Alcoholic cirrhosis</td><td>8 (22.2%)</td></tr><tr><td> Other</td><td>1(2.8%)</td></tr><tr><td colspan="2">Metastastic sites</td></tr><tr><td> Lung</td><td>22 (61.1%)</td></tr><tr><td> Lymph node</td><td>11 (30.6%)</td></tr><tr><td> Bone</td><td>9 (25.0%)</td></tr><tr><td> Other</td><td>11 (30.6%)</td></tr><tr><td colspan="2">ECOG PS</td></tr><tr><td> 0</td><td>23 (63.9%)</td></tr><tr><td> 1</td><td>13 (36.1%)</td></tr><tr><td> 2</td><td>0 (0.0%)</td></tr><tr><td colspan="2">Any prior therapy</td></tr><tr><td> Sorafenib</td><td>31 (86.1%)</td></tr><tr><td> Locoregional therapy<sup>a</sup></td><td>31 (86.1%)</td></tr><tr><td colspan="2">AFP</td></tr><tr><td>&lt; 200 ng/mL</td><td>22 (61.1%)</td></tr><tr><td>&#8805; 200 ng/mL</td><td>14 (38.9%)</td></tr><tr><td colspan="2">PIVKA</td></tr><tr><td>&lt; 400 mAU/mL</td><td>17 (47.2%)</td></tr><tr><td>&#8805; 400 mAU/mL</td><td>19 (52.8%)</td></tr></table>
8b46ee8a85a812465ddd4d2cc47315d5fe4dab703ad059fce6a671bbe08b6a69.png
complex
<table><tr><td>Name</td><td><i>P</i>-value</td><td>Number of molecules</td></tr><tr><td colspan="3">Molecular and Cellular Functions</td></tr><tr><td>Cell Death and Survival</td><td>2.53 &#215; 10<sup>&#8722;24</sup> to 1.36 &#215; 10<sup>&#8722;3</sup></td><td>405</td></tr><tr><td>Cellular Growth and Proliferation</td><td>3.37 &#215; 10<sup>&#8722;24</sup> to 1.36 &#215; 10<sup>&#8722;3</sup></td><td>414</td></tr><tr><td>Cellular Movement</td><td>5.41 &#215; 10<sup>&#8722;13</sup> to 1.36 &#215; 10<sup>&#8722;3</sup></td><td>236</td></tr><tr><td>Gene Expression</td><td>8.14 &#215; 10<sup>&#8722;11</sup> to 1.20 &#215; 10<sup>&#8722;3</sup></td><td>247</td></tr><tr><td>Cellular Development</td><td>1.13 &#215; 10<sup>&#8722;10</sup> to 1.36 &#215; 10<sup>&#8722;3</sup></td><td>328</td></tr><tr><td colspan="3">Physiological System Development and Function</td></tr><tr><td>Cardiovascular System Development and Function</td><td>4.17 &#215; 10<sup>&#8722;12</sup> to 1.20 &#215; 10<sup>&#8722;3</sup></td><td>125</td></tr><tr><td>Organismal Development</td><td>3.96 &#215; 10<sup>&#8722;11</sup> to 1.22 &#215; 10<sup>&#8722;3</sup></td><td>92</td></tr><tr><td>Tissue Development</td><td>3.68 &#215; 10<sup>&#8722;8</sup> to 1.22 &#215; 10<sup>&#8722;3</sup></td><td>163</td></tr><tr><td>Tumor Morphology</td><td>3.84 &#215; 10<sup>&#8722;7</sup> to 1.20 &#215; 10<sup>&#8722;3</sup></td><td>117</td></tr><tr><td>Connective Tissue Development and Function</td><td>8.52 &#215; 10<sup>&#8722;6</sup> to 1.24 &#215; 10<sup>&#8722;3</sup></td><td>40</td></tr></table>
26b46a7a8a5b335885b29fe47aca977bb7e6eca92c9e9c2de45cce3046fddb22.png
simple
<table><tr><td>Confinement</td><td>CNVR</td><td>VMR</td><td>Total</td></tr><tr><td>Free Roaming</td><td>1441</td><td>4812</td><td>6253</td></tr><tr><td>Presented by owner</td><td>20</td><td>631</td><td>651</td></tr><tr><td>Total</td><td>1461</td><td>5443</td><td>6904</td></tr></table>
95482bca05ce3eaed84abe6d216968d37abafda74ce8b0069d2f0491f6bcb8be.png
simple
<table><tr><td>Database</td><td># Of Genes in Database</td><td>Last Updated <sup>1</sup></td><td>Database Source</td></tr><tr><td>ShortBRED VF <sup>2</sup></td><td>26,187</td><td>July 2017</td><td>https://huttenhower.sph.harvard.edu/shortbred</td></tr><tr><td>ShortBRED AR <sup>3</sup></td><td>932</td><td>July 2017</td><td>https://huttenhower.sph.harvard.edu/shortbred</td></tr><tr><td>Virulence Factor DataBase (VFDB)</td><td>30,246</td><td>February 2018</td><td>http://www.mgc.ac.cn/VFs/main.htm</td></tr><tr><td>Comprehensive Antibiotic Resistance Database (CARD)</td><td>2514</td><td>February 2018</td><td>https://card.mcmaster.ca/download</td></tr></table>
6fa49408dcb50095cb6036ff676cd110697f3dc0f5f7e2334f71683a22e6c920.png
simple
<table><tr><td>No.</td><td>Antibiotic</td><td>Abbr.</td><td>Concentration (&#956;g)</td><td>Class</td></tr><tr><td>1.</td><td>Amikacin</td><td>AK</td><td>30</td><td>Aminoglycosides</td></tr><tr><td>2.</td><td>Amoxicillin/clavulanic acid<sup>a</sup></td><td>AMC</td><td>30</td><td>3rd generation penicillins</td></tr><tr><td>3.</td><td>Ampicillin</td><td>AMP</td><td>10</td><td>Aminoglycosides</td></tr><tr><td>4.</td><td>Aztreonam</td><td>ATM</td><td>30</td><td>Monobactams</td></tr><tr><td>5.</td><td>Cefamandole</td><td>MA</td><td>30</td><td>2nd generation cephalosporins</td></tr><tr><td>6.</td><td>Cefepime</td><td>FEP</td><td>30</td><td>4th generation cephalosporins</td></tr><tr><td>7.</td><td>Cefotaxime<sup>a</sup></td><td>CTX</td><td>30</td><td>3rd generation cephalosporins</td></tr><tr><td>8.</td><td>Cefoxitin</td><td>FOX</td><td>30</td><td>3rd generation cephalosporins</td></tr><tr><td>9.</td><td>Ceftazidime<sup>a</sup></td><td>CAZ</td><td>30</td><td>3rd generation cephalosporins</td></tr><tr><td>10.</td><td>Cefalotin</td><td>KF</td><td>30</td><td>3rd generation cephalosporins</td></tr><tr><td>11.</td><td>Cefazolin</td><td>KZ</td><td>30</td><td>1st generation cephalosporins</td></tr><tr><td>12.</td><td>Ciprofloxacin</td><td>CIP</td><td>5</td><td>Chinolons</td></tr><tr><td>13.</td><td>Gentamicin</td><td>CN</td><td>10</td><td>Aminoglycosides</td></tr><tr><td>14.</td><td>Netilmicin</td><td>NET</td><td>30</td><td>Aminoglycosides</td></tr><tr><td>15.</td><td>Piperacillin</td><td>PRL</td><td>100</td><td>4th generation penicillins</td></tr><tr><td>16.</td><td>Piperacillin/tazobactam</td><td>TZP</td><td>110</td><td>4th generation penicillins</td></tr><tr><td>17.</td><td>Tetracycline</td><td>TE</td><td>30</td><td>Tetracyclines</td></tr><tr><td>18.</td><td>Ticarcyillin</td><td>TIC</td><td>75</td><td>4th generation penicillins</td></tr><tr><td>19.</td><td>Tobramycin</td><td>TOB</td><td>10</td><td>Aminoglycosides</td></tr><tr><td>20.</td><td>Trimethoprim/sulfamethoxazole</td><td>SXT</td><td>25</td><td>Sulfonamides</td></tr></table>
479c42f5ebf52b3f77a00f616f5313897c96bde31052cdb8f4f7824a75091b6f.png
simple
<table><tr><td>Variable</td><td>Diabetes case ascertainment cohort <i>n </i>(%)</td><td>Comorbidity case ascertainment cohort <i>n </i>(%)</td></tr><tr><td>Age group</td><td> </td><td> </td></tr><tr><td> &lt; 65 years</td><td>1518 (6.5)</td><td>300 (7.2)</td></tr><tr><td> 65 &#8211; 74 years</td><td>2090 (9.0)</td><td>554 (13.2)</td></tr><tr><td> 75 &#8211; 84 years</td><td>7187 (31.0)</td><td>1517 (36.3)</td></tr><tr><td> 85+ years</td><td>12422 (53.5)</td><td>1812 (43.3)</td></tr><tr><td>Sex</td><td> </td><td> </td></tr><tr><td> Female</td><td>14795 (63.7)</td><td>2547 (60.9)</td></tr><tr><td> Male</td><td>8422 (36.3)</td><td>1636 (39.1)</td></tr><tr><td>Charlson comorbidity index</td><td> </td><td> </td></tr><tr><td> 0</td><td>7947 (34.2)</td><td>1108 (26.5)</td></tr><tr><td> 1-2</td><td>9467 (40.8)</td><td>1552 (37.1)</td></tr><tr><td> 3+</td><td>5803 (25.0)</td><td>1523 (36.4)</td></tr><tr><td>Income quintile</td><td> </td><td> </td></tr><tr><td> Q1 (Lowest)</td><td>5400 (23.3)</td><td>1097 (26.2)</td></tr><tr><td> Q2</td><td>4814 (20.7)</td><td>887 (21.2)</td></tr><tr><td> Q3</td><td>5639 (24.3)</td><td>983 (23.5)</td></tr><tr><td> Q4</td><td>4072 (17.5)</td><td>693 (16.6)</td></tr><tr><td> Q5 (Highest)</td><td>3143 (13.5)</td><td>500 (12.0)</td></tr><tr><td> Missing</td><td>149 (0.6)</td><td>23 (0.5)</td></tr><tr><td>Residence location</td><td> </td><td> </td></tr><tr><td> Rural</td><td>11796 (50.8)</td><td>2197 (52.5)</td></tr><tr><td> Urban</td><td>11209 (48.3)</td><td>1932 (46.2)</td></tr><tr><td> Missing</td><td>212 (0.9)</td><td>54 (1.3)</td></tr><tr><td>Facility affiliation</td><td> </td><td> </td></tr><tr><td> Affiliated</td><td>6834 (29.4)</td><td>1160 (27.7)</td></tr><tr><td> Amalgamated</td><td>14412 (62.1)</td><td>2686 (64.2)</td></tr><tr><td> Contract</td><td>1968 (8.5)</td><td>334 (8.1)</td></tr><tr><td>Facility type</td><td> </td><td> </td></tr><tr><td> Special care home</td><td>20002 (90.5)</td><td>3787 (90.5)</td></tr><tr><td> Other facility</td><td>2215 (9.5)</td><td>396 (9.5)</td></tr><tr><td>Diabetes prevalence (%)</td><td>6298 (27.1)</td><td>4183 (100.0)</td></tr></table>
f77a63c3b0d8a2bf63d24dcced3c5e54b554250206fe6ce901315bda016cc760.png
simple
<table><tr><td>Stakeholders&#8217; designation</td><td>Number of participants</td></tr><tr><td>Mobile phone programming company</td><td>1</td></tr><tr><td>Clinicians</td><td>4</td></tr><tr><td>Community health workers</td><td>4</td></tr><tr><td>Research team</td><td>4</td></tr><tr><td>District health management teams</td><td>10</td></tr><tr><td>Total</td><td>23</td></tr></table>
c6e1ae86fc6e6cf096456612a078c07da75e430299d1c19b3eb8328b74bb0a30.png
complex
<table><tr><td>CHP per subject</td><td colspan="2">Number of subjects (%)</td><td>Number of conditions</td><td>CHP/subj average</td><td>Column-%</td></tr><tr><td>0 = MM0</td><td>17,273</td><td>(19.7)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>1 = MM1</td><td>14,328</td><td>(16.3)</td><td>14,328</td><td>1</td><td>4.7</td></tr><tr><td>2 = MM2</td><td>12,762</td><td>(14.5)</td><td>25,524</td><td>2</td><td>8.4</td></tr><tr><td>3 = MM3</td><td>10,350</td><td>(11.8)</td><td>31,050</td><td>3</td><td>10.3</td></tr><tr><td>4-5 = MM4-5</td><td>14,199</td><td>(16.2)</td><td>62,939</td><td>4.4</td><td>20.8</td></tr><tr><td>6-10 = MM6-10</td><td>14,365</td><td>(16.4)</td><td>107,314</td><td>7.5</td><td>35.4</td></tr><tr><td>11+ = MM11+</td><td>4,560</td><td>(5.2)</td><td>61,653</td><td>13.5</td><td>20.4</td></tr><tr><td>Total</td><td>87,837</td><td>(100,1)</td><td>302,808</td><td>3.4</td><td>100</td></tr></table>
08781ab6abdc97264bd333d6354ae75b08b0f3189dec7e6e82087cc1cb805b0d.png
complex
<table><tr><td>N = 3520</td><td>Total number of women</td><td>%</td><td>95% CIs</td></tr><tr><td colspan="4">Given information during pregnancy (Told about pregnancy complications or told where to go for pregnancy complications or advised to use a skilled birth attendant)</td></tr><tr><td>Yes</td><td>2,872</td><td>81.6</td><td>78.5 to 84.4</td></tr><tr><td colspan="4">Iron tablets/syrup taken</td></tr><tr><td>Yes</td><td>3,214</td><td>91.3</td><td>89.3 to 93.0</td></tr><tr><td colspan="4">Given intestinal parasite drugs</td></tr><tr><td>Yes</td><td>2,250</td><td>63.9</td><td>60.8 to 66.9</td></tr><tr><td colspan="4">Two or more tetanus injections given</td></tr><tr><td>Yes</td><td>3,033</td><td>86.2</td><td>84.2 to 87.9</td></tr><tr><td colspan="4">Blood pressure measured</td></tr><tr><td>Yes</td><td>3,043</td><td>86.4</td><td>83.9 to 88.6</td></tr><tr><td colspan="4">Blood sample taken</td></tr><tr><td>Yes</td><td>1,595</td><td>45.3</td><td>41.8 to 48.9</td></tr><tr><td colspan="4">Urine sample taken</td></tr><tr><td>Yes</td><td>1,968</td><td>55.9</td><td>52.4 to 59.3</td></tr><tr><td colspan="4">Received all seven ANC components</td></tr><tr><td> </td><td>854</td><td>24.3</td><td>21.6 to 27.2</td></tr></table>
9f3a03c8965884bddc11556d02c2e1814f761565b27f6cbcc2faf94e55c5a955.png
simple
<table><tr><td>Early events in the disease course</td><td>EDSS outcome in patients with long term follow-up (&#8805; 100 months)(median, range; N)</td><td>p-level</td></tr><tr><td>Motor symptoms at first myelitis*Sensory symptoms at first myelitis*</td><td>7 (1.5-10; 29)5.25 (2-9; 16)</td><td>p &lt; 0.04<sup>&#167;</sup></td></tr><tr><td>Motor symptoms at onsetSensory symptoms at onset</td><td>8.25 (5.5-10; 8)4 (2-6.5; 5)</td><td>p &lt; 0.007<sup>&#167;</sup></td></tr><tr><td>Tetraparesis at first myelitis*Motor symptoms other than tetraparesis at first myelitis*</td><td>8.25 (7-10; 8)6 (1.5-10; 21)</td><td>p &lt; 0.003<sup>&#167;</sup></td></tr><tr><td>&gt; 1 myelitis attacks during the first year1 myelitis attack during the first year</td><td>8 (2.5-10; 7)5.5 (2-8.5; 11)</td><td>p &lt; 0.035<sup>&#167;</sup></td></tr></table>
6981022024a9003a4ae09730022dd108655f4f232f0dab9d6cc6ac6bdeba2bcd.png
simple
<table><tr><td></td><td>18S+28S vs. 18S+28S</td><td>18S+28S vs. cox1+cox3</td><td>18S+28S vs. tufA</td><td>cox1+cox3 vs. 18S+28S</td><td>cox1+cox3 vs. cox1+cox3</td><td>cox1+cox3 vs. tufA</td><td>tufA vs. 18S+28S</td><td>tufA vs. cox1+cox3</td><td>tufA vs. tufA</td></tr><tr><td>BP</td><td>0.989</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>KH</td><td>1</td><td>0.021</td><td>0.04</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>SH</td><td>1</td><td>0.021</td><td>0.04</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>WSH</td><td>1</td><td>0.032</td><td>0.04</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>AU</td><td>0.994</td><td>0</td><td>0</td><td>0</td><td>0.235</td><td>0</td><td>0</td><td>0</td><td>0.235</td></tr><tr><td>ln</td><td>&#8722;3114.161</td><td>&#8722;3217.96</td><td>&#8722;3192.395</td><td>&#8722;3213.426</td><td>&#8722;2301.843</td><td>&#8722;2819.113</td><td>&#8722;1822.457</td><td>&#8722;1667.534</td><td>&#8722;1259.645</td></tr></table>
d6c68b971be9b7d31de745c9b5a2148bb3f2d128b1d94ebabb8dc32ee81b28bc.png
simple
<table><tr><td>Parameter</td><td>Estimate</td><td>SE</td><td><i>T</i></td><td><i>i</i></td></tr><tr><td>Intercept</td><td>0.974</td><td>0.261</td><td>3.736</td><td>&lt;0.001</td></tr><tr><td>Species</td><td>&#8722;2.028</td><td>0.369</td><td>&#8722;5.500</td><td>&lt;0.001</td></tr><tr><td>Acc.Temp</td><td>&#8722;0.057</td><td>0.018</td><td>&#8722;3.231</td><td>0.001</td></tr><tr><td>Species &#215; Acc.Temp</td><td>0.111</td><td>0.025</td><td>4.419</td><td>&lt;0.001</td></tr></table>
da88215a3e8b18af164e755202b29ec19b77a8d986eb92fcc31f2c09b17e4cf2.png
complex
<table><tr><td rowspan="2">Toxicity</td><td colspan="5">Number of Patients Reporting Toxicity by Grade<sup>a</sup>(<i>N</i> = 24 total toxicities)</td><td rowspan="2">Total</td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr><tr><td>Pain</td><td>2</td><td>7</td><td>0</td><td>0</td><td>0</td><td>9</td></tr><tr><td>Fatigue</td><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2</td></tr><tr><td>Pneumonia</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>2</td></tr><tr><td>Pneumothorax</td><td>0</td><td>2</td><td>0</td><td>0</td><td>0</td><td>2</td></tr><tr><td>Atrial Fibrillation (uncontrolled)</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>1</td></tr><tr><td>Dyspnea</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Respiratory failure</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>1</td></tr><tr><td>Post-Operative Bleeding</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Broncho-pleural Fistula</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Generalized Weakness</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Nausea</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Vomiting</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Anorexia</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td></tr></table>
cfac757d462ad7643c357bad3964e9555e68b1e0887adddc972d9bb5e9a6e259.png
complex
<table><tr><td colspan="2">Variables (Percentage)</td></tr><tr><td>No. patients</td><td>74</td></tr><tr><td>Age (years)</td><td></td></tr><tr><td> Mean</td><td>59.8 &#177; 15.6</td></tr><tr><td> Median</td><td>62</td></tr><tr><td>Sex (female/male)</td><td>53/47</td></tr><tr><td>Mechanically ventilated</td><td>84</td></tr><tr><td>Oxygen by</td><td></td></tr><tr><td> Mask</td><td>9</td></tr><tr><td> Nasal tube</td><td>7</td></tr><tr><td>Central venous line</td><td>76</td></tr><tr><td>Intra-arterial catheter</td><td>92</td></tr><tr><td>Peripheral venous line</td><td>87</td></tr><tr><td>Vasopressor/inotropic drugs</td><td>53</td></tr><tr><td>APACHE II score</td><td>20 &#177; 8.1</td></tr><tr><td>Duration of transfer (min)</td><td>51.3 &#177; 19.1</td></tr><tr><td>Reason transfer</td><td></td></tr><tr><td>Logistic</td><td>20</td></tr><tr><td>Advanced therapy</td><td>80</td></tr></table>
f11fe335754458027d7fbe7ec0a257d2b8f893ab209b638d0623909cf1724713.png
simple
<table><tr><td></td><td>IQ</td><td>Working memory</td><td>Inhibitory control</td><td>Emotion recognition</td></tr><tr><td>Working memory</td><td>.39</td><td></td><td></td><td></td></tr><tr><td>Inhibitory control</td><td>.21</td><td>.11</td><td></td><td></td></tr><tr><td>Emotion recognition</td><td>&#8722;.16</td><td>&#8722;.11</td><td>&#8722;.09</td><td></td></tr><tr><td>ADHD hyperactive-impulsive</td><td>&#8722;.16</td><td>&#8722;.13</td><td>&#8722;.07</td><td>.09</td></tr><tr><td>ADHD inattentive</td><td>&#8722;.21</td><td>&#8722;.19</td><td>&#8722;.12</td><td>.09</td></tr><tr><td>Social cognition</td><td>&#8722;.14</td><td>&#8722;.11</td><td>&#8722;.05</td><td>.10</td></tr><tr><td>Pragmatic language</td><td>&#8722;.25</td><td>&#8722;.18</td><td>&#8722;.06</td><td>.08</td></tr></table>